



Council of the
European Union

144091/EU XXVII. GP
Eingelangt am 08/06/23

Brussels, 8 June 2023
(OR. en)

Interinstitutional File:
2022/0417(COD)

9674/1/23
REV 1

PHARM 84
SAN 259
MI 442
COMPET 471
CODEC 932
VETER 62
IA 118

NOTE

From:	General Secretariat of the Council
To:	Council
Subject:	Regulation on fees and charges payable to EMA - <i>General approach</i>

I. INTRODUCTION

1. The EMA fees system plays a key part in funding the collective regulatory system at EU and national level and in ensuring coverage of the relevant costs. In place since 1995, EMA fees are charged to marketing authorisation holders and applicants for obtaining and maintaining Union-wide marketing authorisations for medicinal products for human and veterinary use.

The fees should ensure adequate funding to guarantee the future sustainability of operations of the EMA while also providing sufficient support to the National Competent Authorities (NCAs) in the Member States.

In 2021, the EMA got 90% of its funding¹ from these fees (roughly €342m out of €380m). Of this €342m, roughly €140m was paid to the NCAs to compensate them for their work in such things as the scientific evaluation of applications (which the EMA coordinates) and other services provided to EMA. Remuneration to the NCAs from EMA is, therefore, an important factor for many NCAs, including in deciding how to contribute with services to provide to EMA.

2. On 13 December 2022, the Council received the Commission proposal for a Regulation of the European Parliament and of the Council on fees and charges payable to the European Medicines Agency, amending Regulation (EU) 2017/745 of the European Parliament and of the Council and repealing Council Regulation (EC) No 297/95 and Regulation (EU) 658/2014 of the European Parliament and of the Council². The proposal has three objectives:
- (i) to move from a flat-rate system to a cost-based system for EMA fees as foreseen in existing legislation³;
 - (ii) to ensure the sustainability of the European regulatory network formed by the EMA and National Competent Authorities (NCAs);
 - (iii) to simplify exiting legislation by merging the content of the two current EMA Fee Regulations⁴ for pharmacovigilance and non-pharmacovigilance fees into one single legal instrument.

The legal bases of the proposal are Article 114 TFEU and Article 168(4), points (b) and (c) TFEU.

¹ The other 10% came from the EU budget

² 16070/22 + ADDS 1-7

³ Article 12 of Council Regulation (EC) No 297/95 and recital 7 of Regulation (EU) 658/2014 of the European Parliament and of the Council

⁴ Council Regulation (EC) No 297/95 and Regulation (EU) No 658/2014 of the European Parliament and of the Council

3. Member States' National Parliaments were consulted on the compliance of the proposed provisions with the principle of subsidiarity and proportionality. The opinions received from the Italian Chamber of Deputies⁵, the Portuguese Parliament⁶ and the Spanish Parliament⁷ considered that the proposal complied with the subsidiarity principle.
4. The ENVI Committee of the European Parliament has appointed Cristian-Silviu BUSOI (RO, EPP) as rapporteur. The Committee is expected to vote on its amendments on 26-27 June 2023.
5. On 24 January 2023, the European Economic and Social Committee decided to issue an opinion endorsing the proposed text⁸. On 31 January 2023, the Committee of the Region's Commission on Natural Resources decided not to issue an opinion on this proposal⁹.
6. The Working Party on Pharmaceuticals and Medical Devices examined the proposal at its meetings of 26, 27 January, 2, 13 and 20 February 2023.
7. On 14 March 2023, the Council held a policy debate on the proposal on the basis of a Presidency Steering Note¹⁰. There was broad support in Council for the way forward proposed by the Presidency as regards both a targeted approach to adjusting the fees and remuneration and flexibility.

⁵ 7647/23 and 9145/23

⁶ 7497/23

⁷ 7615/23

⁸ 9193/23

⁹ 6503/23

¹⁰ 6089/23

II. STATE OF PLAY

8. Following the Council, the Working Party on Pharmaceuticals and Medical Devices examined a series of Presidency compromises at its meetings of 27 March¹¹, 28 March¹², 27 April¹³, 11 May¹⁴ and 22 May 2023¹⁵. Following further consultations, the Working Party on Pharmaceuticals and Medical Devices supported the Presidency compromise text¹⁶ on 24 May 2023.
9. The Permanent Representatives Committee, at its meeting of 31 May 2023, endorsed the Presidency compromise text¹⁷. The Commission reserved its position at this stage, stressing two issues of concern: some increases in fees were not in line with the cost-based principle and the weakening of the empowerment of the Commission, notably regarding a change in the statutory tasks of the Agency.
10. The Presidency compromise text implemented the way forward supported at Council as follows:

¹¹ 7350/23
¹² 7350/1/23 REV 1
¹³ 8423/23
¹⁴ 8903/23
¹⁵ 8903/1/23 REV 1
¹⁶ 8903/2/23 REV 2
¹⁷ Annex to the Annex of 9277/23

10.1. Targeted approach to adjusting fees and remuneration

Fees and remuneration have been adjusted in a two-step approach.

(i) Horizontal adjustments

For the human parts of the proposal, an adjustment of roughly 13% for inflation has been applied to the amounts in Annexes I, III and IV for the annual inflation rates for the calendar years 2021 and 2022¹⁸.

However, as regards the veterinary parts of the proposal, given the need expressed by some Ministers for a balance between the sustainability of the network and the viability of industry when setting the fees and remuneration, the adjustment for inflation applied to the amounts in Annex II takes into account only fifty percent of the annual inflation rates for the calendar years 2021 and 2022¹⁹.

Given the emphasis placed by Ministers on the sustainability of the Union regulatory network, roughly 7% has been added as a sustainability factor for NCAs to the remuneration paid to them resulting in a total horizontal adjustment of 20%. The fees have then been adjusted accordingly. In addition, a provision has been added²⁰ stating that any revision of the fees and charges and of the remuneration paid to competent authorities of the Member States provided for in this Regulation should take into account also the sustainability of the Union regulatory network including a fair and objective allocation of fees, charges and remuneration.

¹⁸ See recital 24

¹⁹ See recital 16

²⁰ See Article 11(2)

(ii) Targeted adjustments

Once these horizontal adjustments had been made, further adjustments have been made to the following seven procedures supported by Ministers²¹:

- Scientific Advice (Annex I, point 1)
- Generics (Annex I, point 3.6 & 3.8)
- Type II variations (Annex I, point 5)
- Referrals (Annex I, point 6)
- Periodic safety update reports (PSURS) (Annex I, point 14)
- Inspections (Annex IV, point 1)
- Pharmacovigilance Risk Assessment Committee (PRAC) rapporteurship (new fee and remuneration required).

In addition, in order to avoid distorting incentives, the fees and remuneration for rolling reviews and compassionate use (Annex I, point 2.1) have been aligned to those for market authorisations (Annex I, point 3.1). Furthermore, an additional fee for rolling reviews has been added given the additional work that they involve (Annex I, point 2.1a(new)).

10.2 Flexibility

Flexibility and future-proofing have been applied in two main ways.

- i) In *Article 10 on transparency and monitoring*, the EMA Management Board will approve the special report and the Executive Director of the Agency is obliged to prepare a special report if asked by the Management Board;

²¹ See 6089/23, paragraph 6(a).

- ii) In *Article 11 on revision* (by delegated acts), Ministers had supported removing one of the powers delegated to the Commission by allowing the Board to adopt a special report with justified recommendations to adapt the specification of activities for which the Agency collects fees or charges to changing conditions and requirements²². The Commission is empowered to adopt a delegated act once it has received such a special report²³. It is now suggested also to use the same model to allow the Board to adopt a special report with justified recommendations to increase, decrease or introduce any fee, charge or remuneration following a change in the statutory tasks of the Agency leading to a significant change in its costs²⁴. In the light of this, Article 11(1)(c) and (e) have been deleted.

III. CONCLUSION

11. In the light of the above, Council is invited to reach a general approach on the text, as set out in Annex to this Note, at its session on 13 June 2023, and also to mandate the Presidency to enter into negotiations on the file with representatives of the European Parliament on this basis.

²² See Article 10(6)(c)
²³ See Article 11(1)(a)
²⁴ See Article 10(6)(d)

Proposal for a

REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

on fees and charges payable to the European Medicines Agency, amending Regulations (EU) 2017/745 and (EU) 2022/123 of the European Parliament and of the Council and repealing Council Regulation (EC) No 297/95 and Regulation (EU) 658/2014 of the European Parliament and of the Council

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 114 and Article 168(4), points (b) and (c), thereof,

Having regard to the proposal from the European Commission,

After transmission of the draft legislative act to the national parliaments,

Having regard to the opinion of the European Economic and Social Committee²⁵,

Having regard to the opinion of the Committee of the Regions²⁶,

Acting in accordance with the ordinary legislative procedure,

Whereas:

²⁵ OJ C , , p. .

²⁶ OJ C , , p. .

- (1) The European Medicines Agency ('the Agency') plays a key role in ensuring that only safe, high-quality and efficacious medicinal products are placed on the Union market, thus contributing to the smooth functioning of the internal market and ensuring a high level of protection of human and animal health. It is therefore necessary to ensure sufficient resources are available to the Agency to finance its activities, including resources emanating from fees, and to remunerate in a sustainable manner the fundamental contribution of competent authorities of Member States to the scientific assessments of the Agency.
- (2) The general objective of this Regulation is to contribute to setting high standards of quality and safety for medicinal products for human use and veterinary medicinal products and to ensuring high level of protection of public and animal health, by providing a sound financial basis for the operations of the Agency. It establishes cost-based fees and charges to be levied by the Agency, as well as cost-based remuneration to competent authorities of the Member States for the services they provide for the completion of the Agency's statutory tasks. Such remuneration should be provided through a single Union remuneration amount per relevant type of fee, regardless of the Member State of origin of the competent authority. Cost-based fees should take into account an evaluation of costs of the Agency's activities and of the contributions of competent authorities of the Member States to its work. In addition, this Regulation aims to establish a single framework for a streamlined fee system of the Agency and to introduce regulatory flexibility for adjustment to that fee system in the future.
- (2a) This Regulation should only regulate fees and charges which are to be levied by the Agency, whereas the competence to decide on possible fees levied by the national competent authorities remains with the Member States. Applicants and marketing authorisation holders are not to be charged twice for the same activity.

- (3) The fees payable to the Agency should be proportionate to the work carried out in relation to obtaining and maintaining a Union authorisation, and should be based on an evaluation of the Agency's estimations and forecasts as regards the workload and related costs for that work, as well as on an evaluation of the costs of the services provided to the Agency by the competent authorities of Member States that are responsible for regulating medicinal products, which act as rapporteurs and, where applicable, co-rapporteurs appointed by the scientific committees of the Agency.
- (4) Pursuant to Article 67(3) of Regulation (EC) No 726/2004 of the European Parliament and of the Council²⁷, the revenue of the Agency consists of a contribution from the Union, a contribution from third countries participating in the work of the Agency with which the Union has concluded international agreements for this purpose, fees paid by undertakings for obtaining and maintaining Union marketing authorisations and for services provided by the coordination group as regards the fulfilment of its tasks in accordance with Articles 107c, 107e, 107g, 107k and 107q of Directive 2001/83/EC of the European Parliament and of the Council²⁸, charges for other services provided by the Agency, and Union funding in the form of grants for participation in research and assistance projects, in accordance with the Agency's financial rules and with the provisions of the relevant instruments supporting the policies of the Union.

²⁷ Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency, (OJ L 136 30.4.2004, p. 1).

²⁸ Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67).

- (5) Fees and charges should cover the cost of statutory services and activities of the Agency that is not already covered by the contributions to its revenue from other sources. All relevant Union legislation governing the Agency's activities and fees should be taken into account when establishing the fees and charges, including Regulation (EC) No 726/2004, Regulation (EU) 2019/6 of the European Parliament and of the Council²⁹, Directive 2001/83/EC, Regulation (EC) No 1901/2006 of the European Parliament and of the Council³⁰, Regulation (EC) No 141/2000 of the European Parliament and of the Council³¹, Regulation (EC) No 1394/2007 of the European Parliament and of the Council³², Commission Regulation (EC) No 2049/2005³³, Commission Regulation (EC) No 1234/2008³⁴, Regulation (EU) 2017/745 of the European Parliament and of the Council³⁵, Regulation (EU) 2017/746 of the European Parliament and of the Council³⁶ Regulation (EC) No 470/2009 of the European Parliament

²⁹ Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (OJ L 4, 7.1.2019, p. 43).

³⁰ Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (OJ L 378, 27.12.2006, p. 1).

³¹ Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (OJ L 18, 22.1.2000, p. 1).

³² Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (OJ L 324, 10.12.2007, p. 121).

³³ Commission Regulation (EC) No 2049/2005 of 15 December 2005 laying down, pursuant to Regulation (EC) No 726/2004 of the European Parliament and of the Council, rules regarding the payment of fees to, and the receipt of administrative assistance from, the European Medicines Agency by micro, small and medium-sized enterprises (OJ L 329, 16.12.2005, p. 4).

³⁴ Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (OJ L 334, 12.12.2008, p. 7).

³⁵ Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (OJ L 117, 5.5.2017, p. 1).

³⁶ Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, p. 176)

and of the Council³⁷, Commission Regulation (EU) 2018/782³⁸, Commission Implementing Regulation (EU) 2021/1281³⁹ and Commission Regulation (EC) No 2141/96⁴⁰.

- (6) Pursuant to Article 6(1) of Regulation (EC) No 726/2004, each application for the authorisation of a medicinal product for human use is to be accompanied by the fee payable to the Agency for the examination of that application. Pursuant to Article 43(1) of Regulation (EU) 2019/6, an application for a centralised marketing authorisation for a veterinary medicinal product is to be accompanied by the fee payable to the Agency for the examination of the application.

³⁷ Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 152, 16.6.2009, p. 11).

³⁸ Commission Regulation (EU) 2018/782 of 29 May 2018 establishing the methodological principles for the risk assessment and risk management recommendations referred to in Regulation (EC) No 470/2009 (OJ L 132, 30.5.2018, p. 5).

³⁹ Commission Implementing Regulation (EU) 2021/1281 of 2 August 2021 laying down rules for the application of Regulation (EU) 2019/6 of the European Parliament and of the Council as regards good pharmacovigilance practice and on the format, content and summary of the pharmacovigilance system master file for veterinary medicinal products (OJ L 279, 3.8.2021, p. 15).

⁴⁰ Commission Regulation (EC) No 2141/96 of 7 November 1996 concerning the examination of an application for the transfer of a marketing authorization for a medicinal product falling within the scope of Council Regulation (EC) No 2309/93 (OJ L 286, 8.11.1996, p. 6).

- (7) In line with the Joint Statement of the European Parliament, the Council of the EU and the Commission of 19 July 2012 on decentralised agencies, for bodies for which the revenue is constituted by fees and charges in addition to the Union contribution, fees should be set at a level that avoids a deficit or a significant accumulation of surplus, and should be revised when this is not the case. Therefore, a cost monitoring system should be put in place. The purpose of such monitoring system should be to detect significant changes of costs of the Agency that, taking into account the Union contribution and other non-fee revenue, could require a change in fees, charges or remuneration established under this regulation. That monitoring system should equally be able to detect, based on objective and verifiable information, significant changes of costs of remuneration of services provided to the Agency by the competent authorities of Member States, which act as rapporteurs and, where applicable, co-rapporteurs and by experts contracted by the Agency for the procedures of the expert panels on medical devices. Cost information relating to services remunerated by the Agency should be auditable in accordance with Article 257 of Regulation (EU, Euratom) 2018/1046 of the European Parliament and of the Council⁴¹.

⁴¹ Regulation (EU, Euratom) 2018/1046 of the European Parliament and of the Council of 18 July 2018 on the financial rules applicable to the general budget of the Union, amending Regulations (EU) No 1296/2013, (EU) No 1301/2013, (EU) No 1303/2013, (EU) No 1304/2013, (EU) No 1309/2013, (EU) No 1316/2013, (EU) No 223/2014, (EU) No 283/2014, and Decision No 541/2014/EU and repealing Regulation (EU, Euratom) No 966/2012 (OJ L 193, 30.7.2018, p. 1).

- (8) Fees should be levied on marketing authorisation applicants and holders on a fair basis whereby the fee charged is proportionate to the assessment work. Therefore, for the purpose of charging some post-authorisation fees where products authorised by the Member States are included in the assessment performed by the Agency, a chargeable unit should be established, irrespective not only of the procedure under which the product has been authorised, namely under Regulation (EC) No 726/2004 or Regulation (EU) 2019/6 or Directive 2001/83/EC, but also of the way in which authorisation numbers are assigned by Member States or the Commission. This should not apply to medicinal products for human use authorised to be placed on the market under Article 126a of Directive 2001/83/EC. For medicinal products for human use, that objective should be met by establishing the chargeable unit on the basis of the active substances and the pharmaceutical form of the products that are subject to the obligation to be registered in the database referred to in Article 57(1), second subparagraph, point (l), of Regulation (EC) No 726/2004, based on information from the list of all medicinal products for human use authorised in the Union referred to in Article 57(2), second subparagraph, of that Regulation. The active substances should not be taken into account when establishing the chargeable unit in respect of homeopathic medicinal products or herbal medicinal products. For veterinary medicinal products, the same objective of fairness and proportionality should be met by establishing the chargeable unit based on information contained in the Union product database referred to in Article 55(1) of Regulation (EU) 2019/6, such as the active substances, the pharmaceutical form and the strength of veterinary medicinal products, which are taken into account in the Product Identifier referred to under Data Field ID 3.2 in Annex III to Commission Implementing Regulation (EU) 2021/16⁴², as well as the Permanent Identifier referred to under Data Field ID 3.1 in Annex III to that Implementing Regulation.

⁴² Commission Implementing Regulation (EU) 2021/16 of 8 January 2021 laying down the necessary measures and practical arrangements for the Union database on veterinary medicinal products (Union product database) (OJ L 7, 11.1.2021, p. 1).

- (9) In order to take into account all the marketing authorisations of medicinal products granted to marketing authorisation holders, the number of chargeable units corresponding to those authorisations should take into account the number of Member States in which the marketing authorisation is valid.
- (10) In order to take account of the variety of the statutory tasks of the Agency and of the rapporteurs and, where applicable, co-rapporteurs, fees should be levied per procedure, for costs relating to the assessment of medicinal products for human use and for veterinary medicinal products, and on an annual basis for costs incurred by the Agency for other ongoing activities that it carries out under its mandate that benefit marketing authorisation holders overall. For the purpose of simplification, the costs related to minor variations of Type I and renewals are equally included in the annual fee on the basis of an average estimation.
- (11) An annual fee for medicinal products authorised in accordance with the centralised procedure set out in Regulation (EC) No 726/2004 or the centralised procedure set out in Regulation (EU) 2019/6 should be levied to ensure coverage of the costs connected with the overall post-authorisation supervision and maintenance activities for those products. Those activities include the recording of the actual marketing of medicinal products authorised in accordance with Union procedures, the maintenance of marketing authorisation dossiers and of the various databases managed by the Agency, minor variations of Type I and renewals and activities contributing to a continuous follow-up of the risk-benefit balance of authorised medicinal products. They also comprise access to and analysis of Union-wide health data to support better decision-making throughout the product lifecycle on medicines with valid and reliable real-world evidence. The revenue from that annual fee should be used to fund an annual remuneration of the services of rapporteurs and co-rapporteurs from competent authorities of the Member States for their respective contributions to the supervision and maintenance activities of the Agency.

- (12) A specific annual fee should be charged for medicinal products authorised in accordance with Directive 2001/83/EC and for veterinary medicinal products authorised by the Member States in accordance with Regulation (EU) 2019/6 specifically for the pharmacovigilance activities carried out by the Agency that benefit marketing authorisation holders overall. Those activities relate to information technology, in particular maintenance of the EudraVigilance database referred to in Article 24(1) of Regulation (EC) No 726/2004, the Union product database referred to in Article 55(1) of Regulation (EU) 2019/6 and the Union pharmacovigilance database referred to in Article 74(1) of that Regulation, the monitoring of selected medical literature and the timely access to and analysis of Union-wide health data to support decision-making throughout the product lifecycle on medicines with valid and reliable real-world evidence.
- (13) Charges can be levied for activities and services of an administrative nature, such as issuing certificates, that are not covered by a fee provided for in this Regulation, whereas fees levied by the Agency correspond to services of a scientific nature provided by the Agency under its mandate, which contribute to the assessment relating to medicinal products and the maintenance of authorised products, including a continuous monitoring of the risk-benefit balance. Fees for inspections should be set by distinct inspection. Each distinct inspection should trigger a separate fee.
- (14) Where a fee is reduced by 100 %, the theoretical full amount of that fee should still be provided for, for reasons of transparency and cost recovery.

- (15) In line with union policies, it is appropriate to provide for reductions of the fees to support specific sectors and applicants or marketing authorisation holders, such as micro-, small- and medium-sized enterprises (SMEs), or to respond to specific circumstances, such as products responding to recognised public health or animal health priorities or veterinary medicinal products intended for a limited market authorised in accordance with Article 23 of Regulation (EU) 2019/6.
- (16) The market for veterinary medicinal products is smaller and more fragmented compared to the market for medicinal products for human use. Therefore, it is appropriate to provide for a reduction of the annual fee and of some specific fees for veterinary medicinal products and to closely monitor associated costs for competent authorities of the Member States and the Agency, in order to support the objectives of Regulation (EU) 2019/6. Therefore, the adjustment to inflation applied to the amounts in Annex II takes into account only fifty percent of the annual inflation rates for the calendar years 2021 and 2022.
- (17) The Management Board of the Agency should be empowered to provide further fee or charge reductions for justified reasons of protection of public and animal health or for justified reasons for the support of specific types of products or applicants. A favourable opinion from the Commission should be mandatory before granting further fee reductions, in order to ensure alignment with Union law and with overall policies of the Union. In addition, in duly justified exceptional cases, such as imperative reasons of public or animal health, it should also be possible for the Executive Director of the Agency to reduce certain types of fees on the basis of a critical examination of the situation specific to each case.

- (18) In order to provide flexibility, in particular to adapt to developments in science, the Management Board of the Agency should be enabled to specify working arrangements to facilitate the application of this Regulation, on a duly justified proposal from the Executive Director. In particular, the Management Board should be able to establish due dates and deadlines for payment, payment methods, timetables, detailed classifications, lists of additional fee reductions, detailed amounts within the limits of an established range and a common format sufficiently flexible for financial information to be provided by the National Competent Authorities to the Agency and what constitutes a distinct inspection, for each type of inspection. A favourable opinion from the Commission should be mandatory before the proposal is put to the Management Board for adoption, in order to ensure alignment with Union law and with overall policies of the Union.
- (19) For their assessments, rapporteurs and co-rapporteurs and the other roles considered as equivalent for the purposes of this regulation in scientific advice and inspections rely on the scientific evaluations and resources of the competent authorities of Member States, while it is the responsibility of the Agency to coordinate the existing scientific resources put at its disposal by the Member States, in accordance with Article 55 of Regulation (EC) No 726/2004. In light of that, and to ensure appropriate resources for the scientific assessments relating to the procedures carried out at Union level, the Agency should remunerate the scientific assessment services provided by the rapporteurs and co-rapporteurs appointed by the Member States as members of the scientific committees of the Agency, or, where relevant, provided by rapporteurs and co-rapporteurs in the coordination group referred to in Article 27 of Directive 2001/83/EC. The amount of remuneration for the services provided by those rapporteurs and co-rapporteurs should be based on estimations of the workload involved and should be taken into account in setting the level of the fees charged by the Agency.

- (20) In line with the policy of the Union to support SMEs as defined in Commission Recommendation 2003/361/EC⁴³, fee reductions should apply to them. Such reductions are to be established on a basis that takes due account of the ability of SMEs to pay. In order to ensure consistency of the framework for support to SMEs with Commission Regulation (EC) No 2049/2005⁴⁴, current post-authorisation fee reduction rates should be granted to SMEs. Furthermore, microenterprises should be exempted from all post-authorisation fees.
- (21) Generic medicinal products for human use and generic veterinary medicinal products, medicinal products for human use and veterinary medicinal products authorised under the provisions relating to well-established medicinal use, homeopathic medicinal products for human use and homeopathic veterinary medicinal products, as well as herbal medicinal products for human use should be subject to a reduced annual pharmacovigilance fee, as those medicinal products generally have a well-established safety profile. However, in cases where such medicinal products are subject of any of the pharmacovigilance procedures carried out at Union level, the full fee is to be charged in view of the work involved.
- (22) In order to avoid a disproportionate administrative workload for the Agency, fee reductions and fee exemptions should be applied on the basis of a declaration of the marketing authorisation holder or applicant claiming to be entitled to such a measure. The submission of incorrect information in that respect should be discouraged by means of the application of a specific charge if the Agency establishes that such incorrect information has been submitted.

⁴³ Commission Recommendation of 6 May 2003 concerning the definition of micro, small and medium-sized enterprises (2003/361/EC) (OJ L 124, 20.5.2003, p. 36).

⁴⁴ Commission Regulation (EC) No 2049/2005 of 15 December 2005 laying down, pursuant to Regulation (EC) No 726/2004 of the European Parliament and of the Council, rules regarding the payment of fees to, and the receipt of administrative assistance from, the European Medicines Agency by micro, small and medium-sized enterprises (OJ L 329, 16.12.2005, p. 4).

- (23) For reasons of predictability and clarity, the amounts of the fees, charges and remuneration are set in euro.
- (24) The amounts of the fees and charges and the remuneration to competent authorities of the Member States should be adjusted, where appropriate, to take account of significant changes in costs, detected through cost monitoring, and to take account of inflation. For the purpose of taking into account the impact of inflation, the Harmonised Index of Consumer Prices published by Eurostat pursuant to Regulation (EU) No 2016/792 of the European Parliament and of the Council⁴⁵ should be used. The first adjustment to inflation should take into account the annual inflation rates for each calendar year following the inflation adjustment already applied to the amounts in the Annexes, up to the year 2022 included.

⁴⁵ Regulation (EU) 2016/792 of the European Parliament and of the Council of 11 May 2016 on harmonised indices of consumer prices and the house price index, and repealing Council Regulation (EC) No 2494/95 (OJ L 135, 24.5.2016, p. 11).

(25) In order to ensure swift adjustment of the structure and amounts of fees, charges and remuneration to competent authorities of the Member States to significant changes of costs or processes, the power to adopt acts in accordance with Article 290 of the Treaty on the Functioning of the European Union should be delegated to the Commission in respect of the relevant amounts and the activities subject to fees and charges and remuneration, on the basis of objective information related to costs or changes to the regulatory framework. This information is provided mainly via a special report adopted by the Management Board of the Agency, which contains justified recommendations to increase or decrease the amount of any fee, charge or remuneration, amend the Annexes, including on the basis of changes in the statutory tasks of the Agency, add fees and adapt the specification of activities. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level, and that those consultations be conducted in accordance with the principles laid down in the Interinstitutional Agreement of 13 April 2016 on Better Law-Making⁴⁶. In particular, to ensure equal participation in the preparation of delegated acts, the European Parliament and the Council receive all documents at the same time as Member States' experts, and their experts systematically have access to meetings of Commission expert groups dealing with the preparation of delegated acts. If a change of the fees were to result in an increased share on the side of the Agency, special consideration should be given that the aim of a balanced, objective and fair distribution of fees between the Agency and the competent authorities of the Member States is maintained.

⁴⁶ Interinstitutional Agreement between the European Parliament, the Council of the European Union and the European Commission on Better Law-Making (OJ L 123, 12.5.2016, p. 1).

- (26) In order to ensure cost recovery, the Agency should provide services by virtue of the tasks entrusted to it only after the corresponding fee or charge has been paid in its entirety. However, in accordance with Article 71, fourth subparagraph, of Commission Delegated Regulation (EU) 2019/715⁴⁷, in exceptional circumstances, a service may be provided without prior payment of the corresponding fee or charge.
- (27) In accordance with Article 30 of Regulation (EU) 2022/123⁴⁸, the Agency provides, on behalf of the Commission, the secretariat for the expert panels designated in accordance with Regulation (EU) 2017/745. The provision in Article 106 of Regulation (EU) 2017/745 concerning the payment of fees for advice provided by expert panels should therefore be amended in order to allow the Agency to charge those fees, once such fees are established by the Commission in accordance with that Regulation.
- (28) Since the objective of this Regulation, namely to ensure appropriate funding of Agency activities carried out at Union level, cannot sufficiently be achieved by the Member States but can rather, by reason of the scale of the measure, be better achieved at Union level, the Union may adopt measures, in accordance with the principle of subsidiarity as set out in Article 5 of the Treaty on European Union. In accordance with the principle of proportionality, as set out in that Article, this Regulation does not go beyond what is necessary in order to achieve that objective,
- (28a) In order to allow for the prompt application of the measures provided for in this Regulation, it should enter into force on the day following that of its publication in the Official Journal of the European Union.

HAVE ADOPTED THIS REGULATION:

⁴⁷ Commission Delegated Regulation (EU) 2019/715 of 18 December 2018 on the framework financial regulation for the bodies set up under the TFEU and Euratom Treaty and referred to in Article 70 of Regulation (EU, Euratom) 2018/1046 of the European Parliament and of the Council. (OJ L 122, 10.5.2019, p. 1).

⁴⁸ Regulation (EU) 2022/123 of the European Parliament and of the Council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices (OJ L 20, 31.1.2022, p. 1).

Article 1

Subject matter and scope

1. This Regulation lays down the following:
 - (a) the amounts of the fees and charges established on cost-based evaluation and levied by the European Medicines Agency (the ‘Agency’) for assessment activities relating to obtaining and maintaining a Union authorisation to market medicinal products for human use and veterinary medicinal products and for other services provided or tasks carried out by the Agency, as provided for in Regulations (EC) 726/2004 and (EU) 2019/6;
 - (b) the corresponding amounts of remuneration established on cost-based evaluation and payable by the Agency to the competent authorities of the Member States for the services provided by rapporteurs and, where applicable, co-rapporteurs from competent authorities of the Member States, or by other roles considered as equivalent for the purposes of this regulation, as referred to in the Annexes to this Regulation; and
 - (c) the monitoring of costs of activities and services provided by the Agency and of costs for remuneration referred to in point (b).
2. Medicinal products for human use which are authorised to be placed on the market in accordance with Article 126a of Directive 2001/83/EC shall not be subject to the fees for pharmacovigilance activities set out in the Annexes to this Regulation.

Article 2

Definitions

For the purposes of this Regulation, the following definitions shall apply:

- (1) ‘chargeable unit in relation to medicinal products for human use’ (‘chargeable unit - human’) means a unit defined by a unique combination of the following dataset derived from information on all medicinal products authorised in the Union held by the Agency and consistent with the obligation of marketing authorisation holders referred to in Article 57(2), points (b) and (c), of Regulation (EC) No 726/2004 to submit such information to the database referred to in Article 57(1), second subparagraph, point (l), of that Regulation:
 - (a) name of the medicinal product, as defined in Article 1, point (20), of Directive 2001/83/EC;
 - (b) marketing authorisation holder;
 - (c) the Member State in which the marketing authorisation is valid;
 - (d) active substance or a combination of active substances, except in the case of homeopathic medicinal products or herbal medicinal products, as defined in Article 1, points 5 and 30, respectively, of Directive 2001/83/EC;
 - (e) pharmaceutical form;
- (2) ‘chargeable unit in relation to veterinary medicinal products’ (‘chargeable unit - veterinary’) means a unit defined by the unique combination of the following data fields contained in the Union product database established pursuant to Article 55(1) of Regulation (EU) 2019/6:
 - (a) the Permanent Identifier referred to under Data Field ID 3.1 in Annex III to Implementing Regulation (EU) 2021/16;
 - (b) the Product Identifier referred to under Data Field ID 3.2 in Annex III to Implementing Regulation (EU) 2021/16;

- (3) ‘medium-sized enterprise’ means a medium-sized enterprise within the meaning of Recommendation 2003/361/EC;
- (4) ‘small enterprise’ means a small enterprise within the meaning of Recommendation 2003/361/EC;
- (5) ‘microenterprise’ means a microenterprise within the meaning of Recommendation 2003/361/EC;
- (6) ‘public health emergency’ means a situation of public health emergency recognised by the Commission in accordance with Article 23(1) of Regulation (EU) 2022/2371 of the European Parliament and of the Council⁴⁹.

Article 3

Types of fees and charges

The Agency may levy the following types of fees or charges:

- (a) fees and charges for assessment procedures and services relating to medicinal products for human use, set out in Annex I;
- (b) fees for and charges for assessment procedures and services relating to veterinary medicinal products, set out in Annex II;
- (c) annual fees for authorised medicinal products for human use and for authorised veterinary medicinal products, set out in Annex III;
- (d) other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices, set out in Annex IV.

⁴⁹ Regulation (EU) 2022/2371 of the European Parliament and of the Council of 23 November 2022 on serious cross-border threats to health and repealing Decision No 1082/2013/EU OJ L 314, 6.12.2022, p. 26–63

Article 4

Additional fees and charges

1. The Agency may levy a scientific service fee for scientific services it provides if these services are not covered by another fee or charge provided for in this Regulation. The amount of the scientific service fee shall take into account the workload involved. Its minimum and maximum amount and, where relevant, the corresponding remuneration to the rapporteurs and, where relevant, co-rapporteurs, are set out in point 5 of Annex IV.
2. The Agency may levy a charge for administrative services it provides, at the request of a third party, if these services are not covered by another fee or charge provided for in this Regulation. The amount of the charge for administrative services shall take into account the workload involved. Its minimum and maximum amount are set out in point 6.4 of Annex IV.
3. Fees and charges levied pursuant to paragraphs 1 and 2 shall be set by the Management Board of the Agency following a favourable opinion by the Commission, in accordance with the procedure established under Article 8. The applicable amounts shall be published on the website of the Agency.
4. The Commission shall take into account any fees and charges levied in accordance with this Article in any revision of this Regulation.

Article 5

Payment of remuneration to competent authorities of the Member States for the provision of services to the Agency

1. The Agency shall pay the remuneration referred to in Article 1(b) in accordance with the amounts of remuneration provided for in this Regulation.

2. Unless otherwise provided for in this Regulation, where fee reductions or waivers apply, the remuneration to competent authorities of the Member States payable in accordance with this Regulation shall not be reduced.
3. The remuneration to competent authorities of the Member States shall be paid in accordance with the written contract referred to in Article 62(3), first subparagraph, of Regulation (EC) No 726/2004. The remuneration shall be paid in euro. Any bank charges related to the payment of such remuneration shall be borne by the Agency. Detailed rules concerning the payment of remuneration shall be established by the Management Board of the Agency, in accordance with Article 8 of this Regulation.

Article 6

Reductions of fees and charges

1. The Agency shall apply the reductions set out in Annex V.
2. Where an assessment, an opinion or a service of the Agency is requested either by a Member State or by a Union institution, the Agency may waive the respective fee or charge, as applicable. The Agency shall not levy the respective fee or charge to any Member State or Union institution.
3. Without prejudice to Article 5(2), where the applicant or marketing authorisation holder may also benefit from another reduction provided for in Union legislation, only the reduction that is the most favourable to the applicant or marketing authorisation holder shall apply.

4. On a duly justified proposal from the Executive Director of the Agency, in particular for the protection of public or animal health or for the support of specific types of products or applicants, selected for duly justified reasons, the Management Board of the Agency may grant, following a favourable opinion from the Commission, a total or partial reduction of the applicable fee or charge, in accordance with Article 8.
5. In exceptional circumstances such as imperative reasons of public or animal health, the Executive Director of the Agency may grant, on a case-by-case basis, total or partial reductions for the fees set out in Annexes I, II, III and IV, with the exception of the fees set out in points 6, 14 and 15 of Annex I, points 7 and 10 of Annex II and point 3 of Annex III. Any decision taken pursuant to this Article shall state the reasons on which it is based.

Article 7

Payment of fees and charges

1. Fees and charges due under this Regulation shall be paid in euro.
2. Payment of the fees and charges shall be made after the payer has received a request for payment issued by the Agency specifying the deadline for payment.
3. Payment of the fees and charges shall be made by means of a transfer to the bank account of the Agency specified in the request for payment. Any bank charges related to that payment shall be borne by the payer.
4. The deadline for payment shall be considered to have been complied with only if the full amount has been paid in due time. The date on which the full amount of the payment is received in the bank account held by the Agency shall constitute the date on which the payment has been made.

Article 8

Working arrangements

The Management Board of the Agency shall, on a justified proposal from the Executive Director and following a favourable opinion from the Commission, establish working arrangements to facilitate the application of this Regulation, including payment methods of the fees and charges levied by the Agency, the mechanism for payment of remuneration to competent authorities of the Member States under this Regulation, a total or partial reduction in accordance with Article 6(4) and a common format, based on a transparent methodology, to be used by competent authorities of the Member States when providing to the Agency the financial information in accordance with Article 10(3).

The Management Board of the Agency shall also define in the working arrangements the scope of a distinct inspection, for each type of inspection. This shall include, where relevant, the medicinal product concerned, the site concerned, the activity concerned and the inspection team concerned.

Those arrangements shall be made publicly available on the Agency's website.

Article 9

Due date and measures in case of non-payment

1. By [OP: please insert date of application of this Regulation] the due dates of the fees or charges levied in accordance with this Regulation shall be specified in the working arrangements set out in accordance with Article 8 of this Regulation. Due account shall be taken of the deadlines of the assessment procedures provided for in Regulations (EC) No 726/2004 and (EU) 2019/6 and in Directive 2001/83/EC.

2. Where the payment of any fee or charge levied in accordance with this Regulation is overdue and without prejudice to the Agency's capacity to institute legal proceedings to ensure payment pursuant to Article 71 of Regulation (EC) No 726/2004, the Executive Director of the Agency may decide that the Agency will not provide the services or will not carry out the procedures to which the respective fee or charge relates, or that the Agency will suspend any ongoing or future services and procedures until the respective fee or charge has been paid, including relevant interest as provided for in Article 99 of Regulation (EU, Euratom) 2018/1046.

Article 10

Transparency and monitoring

1. The amounts set out in the annexes shall be published on the website of the Agency.
2. The Agency shall monitor its costs and the Executive Director of the Agency shall provide, as part of the annual activity report delivered to the European Parliament, the Council, the Commission and the Court of Auditors, detailed and substantiated information on the costs to be covered by fees and charges that are within the scope of this Regulation. That information shall include the performance information set out in Annex VI and a cost breakdown related to the previous calendar year and to a forecast for the following calendar year. The Agency shall also publish an overview of that information in its annual report.

3. Evidence of significant changes in the costs of services provided to the Agency, excluding any effect of inflationary adjustments and any costs for activities that do not constitute a service to the Agency, may be provided by competent authorities of the Member States responsible for medicinal products or by experts contracted for the procedures of the expert panels on medical devices to the Agency. Such information may be provided once per calendar year or less frequently, as a complement to the information provided in accordance with Annex VI. Such evidence shall be based on duly justified financial information on the nature and the extent of the financial impact on costs for services to the Agency. To that end, the common format facilitating comparison and consolidation, established in accordance with Article 8 shall be used. The competent authorities of the Member States and the experts contracted to the Agency for the procedures of the expert panels on medical devices shall provide such information in the format provided by the Agency, together with any supporting information allowing to verify the correctness of the amounts submitted. The Agency shall review and aggregate that information and shall use it, in accordance with paragraph 6, as a source for the special report provided for in that paragraph.
4. Article 257 of Regulation (EU, Euratom) 2018/1046 shall apply to the information provided to the Agency in accordance with paragraph 3 of this Article and Annex VI to this Regulation.
5. The Commission shall monitor the inflation rate, measured by means of the Harmonised Index of Consumer Prices published by Eurostat pursuant to Regulation (EU) No 2016/792, in relation to the amounts of fees, charges and remuneration set out in the Annexes to this Regulation. The monitoring shall start at the date [OP: please insert date of application of this Regulation], shall cover the period since the last inflation adjustment and shall thereafter take place on an annual basis. Any adjustment, in line with inflation, to fees, charges and remuneration established in accordance with this regulation shall become applicable, at the earliest, on 1 January of the calendar year following the calendar year in which the monitoring exercise took place.

6. At the earliest on [*OP: please insert date 9 months after the date of application*] and at three-year intervals thereafter, the Executive Director of the Agency shall provide the Commission with a special report adopted by the Management Board of the Agency outlining, in an objective, fact-based and sufficiently detailed manner, justified recommendations to:
- (a) increase or decrease the amount of any fee, charge or remuneration, following a significant change in the respective costs as identified, documented and justified in the report;
 - (b) amend any other element of the Annexes pertaining to the levying of fees and charges, including additional fees and charges referred to in Article 4;
 - (c) adapt the specification of activities for which the Agency collects fees or charges to changing conditions and requirements.
 - (d) increase, decrease or introduce any fee, charge or remuneration following a change in the statutory tasks of the Agency leading to a significant change in its costs;
7. The special report referred to in paragraph 6 and the recommendations it contains shall be based on the following:
- (a) monitoring of the information referred to in paragraphs 2 and 3 and of the cost of the activities necessary for the fulfilment of the statutory tasks of the Agency, aimed at identifying significant changes to the cost base of services and activities of the Agency;
 - (b) objective and verifiable information, including quantification, that directly supports the relevance of the recommended adjustments.

8. The Commission may request any clarification or further substantiation of the report and its recommendations, if considered necessary. Following such a request, the Executive Director of the Agency shall without undue delay provide the Commission with an updated version of the report adopted in accordance with paragraph 6 which addresses any comments made and questions raised by the Commission.
9. The time interval to the first special report as well as the reporting time interval referred to in paragraph 6 may be shortened in any of the following situations:
 - (a) in case of a public health emergency;
 - (b) in case of a change in the statutory tasks of the Agency;
 - (c) in case there is evidence of significant changes in the costs or the cost-revenue balance of the Agency;
 - (d) in case there is evidence of significant changes in the costs for cost-based remuneration to competent authorities of the Member States;
 - (e) upon request of the Management Board of the Agency.

Article 11

Revision

1. The Commission is empowered to adopt delegated acts in accordance with Article 13 to amend the Annexes where justified in view of any of the following:
 - (a) a special report received by the Commission in accordance with Article 10(6);
 - (b) the findings from the monitoring of the inflation rate referred to in Article 10(5);
 - (d) the budgetary reporting of the Agency;
2. Any revision of the fees and charges and of the remuneration paid to competent authorities of the Member States provided for in this Regulation shall be based on the Commission's evaluation of the Agency's costs and revenues and of the full costs of the services provided to the Agency in the scope of this Regulation by the competent authorities of the Member States, taking into account also the sustainability of the Union regulatory network including a fair and objective allocation of fees, charges and remuneration.
3. In any revision of the Annexes, the amounts of remuneration paid to competent authorities of the Member States provided for in this Regulation shall be maintained as single amounts of remuneration irrespective of the Member State of the competent authority concerned.

Article 12

Estimate of the Agency's budget

The Agency shall, when producing an estimate of revenue and expenditure for the following financial year in accordance with Article 67(6) of Regulation (EC) No 726/2004, include detailed information on income from each type of fees and charges and respective remuneration. In accordance with the typology of fees and charges set out in Article 3 of this Regulation, that information shall distinguish, respectively, between the following:

- (a) medicinal products for human use and consultations on medical devices;
- (b) veterinary medicinal products;
- (c) annual fees, by type;
- (d) other fees and charges, by type.

A breakdown by type of procedure may be provided by the Agency in an annex to the single programming document produced in accordance with Article 32(1) of Delegated Regulation (EU) 2019/715.

Article 13

Exercise of the delegation

1. The power to adopt delegated acts is conferred on the Commission subject to the conditions laid down in this Article.
2. The power to adopt delegated acts referred to in Article 11(1) shall be conferred on the Commission for a period of 5 years from *[tbc]* 20*[xx]*. The Commission shall draw up a report in respect of the delegation of power not later than 9 months before the end of the 5-year period. The delegation of power shall be tacitly extended for periods of an identical duration, unless the European Parliament or the Council opposes such extension not later than 3 months before the end of each period.

3. The delegation of power referred to in Article 11(1) may be revoked at any time by the European Parliament or by the Council. A decision to revoke shall put an end to the delegation of the power specified in that decision. It shall take effect the day following the publication of the decision in the *Official Journal of the European Union* or at a later date specified therein. It shall not affect the validity of any delegated acts already in force.
4. Before adopting a delegated act, the Commission shall consult experts designated by each Member State in accordance with the principles laid down in the Interinstitutional Agreement of 13 April 2016 on Better Law-Making.
5. As soon as it adopts a delegated act, the Commission shall notify it simultaneously to the European Parliament and to the Council.
6. A delegated act adopted pursuant to Article 11(1) shall enter into force only if no objection has been expressed either by the European Parliament or the Council within a period of 2 months of notification of that act to the European Parliament and the Council or if, before the expiry of that period, the European Parliament and the Council have both informed the Commission that they will not object. That period shall be extended by 2 months at the initiative of the European Parliament or of the Council.

Article 14

Amendment to Regulation (EU) No 2017/745

Article 106 of Regulation (EU) No 2017/745, paragraph 14 is replaced by the following:

- ‘14. The fees established in accordance with the procedure under paragraph 13 of this Article shall be set in a transparent manner and on the basis of the costs for the services provided. The fees payable shall be reduced in the case of a clinical evaluation consultation procedure initiated in accordance with point (c), of Section 5.1 of Annex IX involving a manufacturer who is a micro, small or medium-sized enterprise within the meaning of Recommendation 2003/361/EC.

The fees related to the advice provided by expert panels are payable to EMA pursuant to Article 30, point (f) of Regulation (EU) 2022/123 of the European Parliament and of the Council.⁵⁰

The fees related to the advice provided by expert laboratories are payable to the Commission.’

⁵⁰ Regulation (EU) 2022/123 of the European Parliament and of the Council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices (OJ L 20, 31.1.2022, p. 1).

Article 14a

Amendment to Regulation (EU) 2022/123

Article 30, point (f) of Regulation (EU) 2022/123, is replaced by the following:

‘(f) charge fees in accordance with Article 106(14) of Regulation (EU) 2017/745 and ensure that remuneration and expenses are provided to experts in accordance with implementing acts adopted by the Commission pursuant to Article 106(1) of Regulation (EU) 2017/745.’.

Article 15

Repeal

Regulations (EC) No 297/95 and (EU) No 658/2014 are repealed as of [*OP: please insert date of application of this Regulation*].

References to Regulation (EC) No 297/95 shall be construed as references to this Regulation and read in accordance with the correlation table in Annex VII to this Regulation.

Article 16

Transitional provisions

This Regulation shall not apply to annual fees, procedures and services for which the amount became due pursuant to Regulation (EC) No 297/95 or Regulation (EU) No 658/2014 before [*OP: please insert date of application of this Regulation*].

Article 17

Entry into force and date of application

This Regulation shall enter into force on the day following that of its publication in the *Official Journal of the European Union*.

It shall apply from [OP: please insert date of 1 January of the calendar year following the year of entry into force of this Regulation if it enters into force by 1 July. In case the Regulation enters into force after 1 July, please insert date of 1 January of the calendar year following expiration of 9 months after entry into force].

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels,

For the European Parliament
The President

For the Council
The President

ANNEX I

Fees, charges and remuneration for assessment procedures and services relating to medicinal products for human use

1. Scientific advice provided by the Agency in accordance with Article 57(1)(n) of Regulation (EC) No 726/2004

1.1. A fee of EUR 79 400 shall apply to any of the following requests:

- (a) a request on quality, non-clinical and clinical development;
- (b) a request on quality and clinical development;
- (c) a request on non-clinical and clinical development;
- (d) a request on qualification of novel methodologies.

The remuneration shall be EUR 20 200 for each of the two scientific advice co-ordinators.

1.2. A fee of EUR 62 900 shall apply to any of the following requests:

- (a) a request on clinical development;
- (b) a request on quality and non-clinical development;
- (c) a request on quality development and bioequivalence studies for generic medicinal products as defined in Article 10(2), point (b) of Directive 2001/83/EC.

The remuneration shall be EUR 13 400 for each of the two scientific advice co-ordinators.

1.3. A fee of EUR 49 600 shall apply to any of the following requests:

- a) a request on quality development;
- b) a request on non-clinical development;
- c) a request on bioequivalence studies for generic medicinal products as defined in Article 10(2), point (b), of Directive 2001/83/EC.

The remuneration shall be EUR 9 700 for each of the two scientific advice co-ordinators.

2. Scientific opinions and assessments prior to potential submission of an application for a marketing authorisation

2.1. A fee of EUR 828 100 shall apply to any of the following:

(a) an opinion on a medicinal product for compassionate use pursuant to Article 83 of Regulation (EC) No 726/2004;

(b) an assessment on an on-going basis of data packages of particulars and documents submitted to the Agency by a prospective applicant prior to a formal submission of an application for a marketing authorisation falling within the scope of Regulation (EC) No 726/2004.

That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application. The remuneration shall be EUR 260 800 for the rapporteur, EUR 227 200 for the co-rapporteur and 24 400 for the PRAC-rapporteur.

2.1a(new) An additional fee of EUR 124 200 shall apply to the assessment set out in point 2.1(b). The remuneration shall be EUR 39 100 for the rapporteur, EUR 34 100 for the co-rapporteur and 3 700 for the PRAC-rapporteur.

2.2. In the event of multiple submissions of data packages submitted by the same prospective applicant for the same product, the fee set out in point 2.1 (b) and 2.1a(new) shall only be charged once.

2.3. The amounts set out in point 2.1 shall be deducted from the respective fee and from the remuneration to competent authorities of the Member States payable for a marketing authorisation application for the same product, where such application is submitted by the same applicant.

3. Authorisation to market a medicinal product falling within the scope of Regulation (EC) No 726/2004

3.1. A fee of EUR 828 100 shall apply to an application for a marketing authorisation for a medicinal product pursuant to Article 8(3) of Directive 2001/83/EC when the applicant claims a new active substance. That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application. The remuneration shall be EUR 260 800 for the rapporteur, EUR 227 200 for the co-rapporteur and 24 400 for the PRAC-rapporteur.

- 3.2. A fee of EUR 661 000 shall apply to an application for a marketing authorisation for a medicinal product pursuant to Article 8(3) of Directive 2001/83/EC when the applicant claims a known active substance. That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application. The remuneration shall be EUR 183 600 for the rapporteur, EUR 172 000 for the co-rapporteur and 17 800 for the PRAC-rapporteur.
- 3.3 A fee of EUR 546 500 shall apply to an application for a fixed combination medicinal product pursuant to Article 10b of Directive 2001/83/EC. That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application. The remuneration shall be EUR 169 800 for the rapporteur, EUR 99 600 for the co-rapporteur and 13 500 for the PRAC-rapporteur.
- 3.4. A fee of EUR 701 100 shall apply to an application for a biological medicinal product which is similar to a reference biological product pursuant to Article 10(4) of Directive 2001/83/EC. That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application. The remuneration shall be EUR 283 800 for the rapporteur, EUR 182 000 for the co-rapporteur and 23 500 for the PRAC-rapporteur.
- 3.5. A fee of EUR 747 300 shall apply to an application for a marketing authorisation for a medicinal product pursuant to Article 10a of Directive 2001/83/EC. That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application. The remuneration shall be EUR 192 700 for the rapporteur, EUR 179 300 for the co-rapporteur and 18 600 for the PRAC-rapporteur.
- 3.6. A fee of EUR 239 500 shall apply to an application for a marketing authorisation for a generic medicinal product pursuant to Article 10(1) of Directive 2001/83/EC.
- That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application. The remuneration shall be EUR 118 900 for the rapporteur and EUR 5 900 for the PRAC-rapporteur.

3.6a (new) A fee of EUR 165 300 shall apply to an application based on informed consent for a marketing authorisation for a medicinal product pursuant to Article 10c of Directive 2001/83/EC.

That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application. The remuneration shall be EUR 48 200 for the rapporteur and EUR 2 400 for the PRAC-rapporteur.

3.7. A fee of EUR 407 800 shall apply to an application for a marketing authorisation for a medicinal product pursuant to Article 10(3) of Directive 2001/83/EC. That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application. The remuneration shall be EUR 106 900 for the rapporteur, EUR 106 900 for the co-rapporteur and 10 700 for the PRAC-rapporteur.

3.8. A fee of EUR 31 800 shall apply to the second and to each subsequent application for a marketing authorisation submitted pursuant to Article 10(1), (3) or (4) of Directive 2001/83/EC on usage patent grounds where the reference medicinal product is subject to a usage patent. That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application. The remuneration shall be EUR 8 200 for the rapporteur and EUR 1 200 for the co-rapporteur.

4. Extension of a marketing authorisation within the meaning of Annex I to Commission Regulation (EC) No 1234/2008⁵¹

4.1. A fee of EUR 161 300 shall apply to an application for an extension of a marketing authorisation requiring only chemical, pharmaceutical or biological documentation and for which no clinical or non-clinical data are submitted. That fee shall cover a single pharmaceutical form and a single associated strength. The remuneration shall be EUR 54 400 for the rapporteur and EUR 31 900 for the co-rapporteur.

4.2. A fee of EUR 188 300 shall apply to an application for an extension of a marketing authorisation not covered by point 4.1. That fee shall cover a single pharmaceutical form and a single associated strength. The remuneration shall be EUR 66 400 for the rapporteur and EUR 37 400 for the co-rapporteur.

4.3. Without prejudice to points 4.1 and 4.2, a fee of EUR 31 800 shall apply to each application for extension of a marketing authorisation on the basis of an application submitted under Article 10(1), (3) or (4) of Directive 2001/83/EC on usage patent grounds as referred to in point 3.8 of this Annex. The remuneration shall be EUR 8 200 for the rapporteur and EUR 1 200 for the co-rapporteur.

⁵¹ Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (OJ L 334, 12.12.2008, p. 7).

5. Major variation of type II to the terms of a marketing authorisation in accordance with Commission Regulation (EC) No 1234/2008

- 5.1. A fee of EUR 175 300 shall apply to an application for a major variation of type II as defined in Article 2(3) of Regulation (EC) No 1234/2008 ('major variation of type II') for an addition of a new therapeutic indication or modification of an approved indication. The remuneration shall be EUR 64 400 for the rapporteur and EUR 64 400 for the co-rapporteur.
- 5.2. A fee of EUR 28 500 shall apply to an application for a major variation of type II not covered by point 5.1. The remuneration shall be EUR 21 500 for the rapporteur.
- 5.3. For each application for a major variation of type II that is grouped in a single application pursuant to Article 7 of Regulation (EC) No 1234/2008, the corresponding fee shall be charged as set out in points 5.1 and 5.2. Remuneration shall be paid in accordance with those points.
- 5.4. Where a work-sharing application pursuant to Article 20 of Regulation (EC) No 1234/2008 includes more than one centrally authorised product, the fees and remuneration specified in points 5.1 and 5.2 of this Annex shall apply to each variation of the first centrally authorised product, whereas a charge of EUR 900 shall apply to each variation of the second and subsequent centrally authorised product included in the application.

6. Referrals and scientific opinions pursuant to Article 5(3) of Regulation (EC) No 726/2004

- 6.1. A fee of EUR 156 700 shall apply to the assessment carried out in the context of a procedure initiated under Article 5(3) of Regulation (EC) No 726/2004. Such fee shall be waived in full. The remuneration shall be EUR 14 900 for the rapporteur and EUR 14 900 for the co-rapporteur.
- 6.2. A fee of EUR 299 800 shall apply to the assessment carried out in the context of a procedure initiated under Article 13 of Regulation (EC) No 1234/2008. Such fee shall be waived in full. The remuneration shall be EUR 18 400 for the rapporteur and EUR 18 400 for the co-rapporteur.
- 6.3. A fee of EUR 94 600 shall apply to the assessment carried out in the context of a procedure initiated under Article 29(4) of Directive 2001/83/EC. Such fee shall be waived in full. The remuneration shall be EUR 3 400 for the rapporteur and EUR 3 400 for the co-rapporteur.

- 6.4. A fee of EUR 146 400 shall apply to the assessment carried out in the context of a procedure initiated under Article 30 of Directive 2001/83/EC. The remuneration shall be EUR 8 200 for the rapporteur and EUR 8 200 for the co-rapporteur.
- 6.5. A fee of EUR 206 700 shall apply to the assessment carried out in the context of a procedure initiated under Article 31 of Directive 2001/83/EC where the procedure is initiated as a result of the evaluation of data other than data relating to pharmacovigilance. The remuneration shall be EUR 14 900 for the rapporteur and EUR 14 900 for the co-rapporteur.
- 6.6. A fee of EUR 197 600 shall apply to the assessment carried out in accordance with a procedure initiated under Article 20 of Regulation (EC) No 726/2004 where that procedure is initiated as a result of the evaluation of data other than data relating to pharmacovigilance. The remuneration shall be EUR 21 000 for the rapporteur and EUR 21 000 for the co-rapporteur
- 6.7. For an assessment carried out in the context of a procedure initiated as a result of the evaluation of pharmacovigilance data under Article 31(1), second subparagraph, Article 31(2) and Articles 107i, 107j and 107k of Directive 2001/83/EC or under Article 20(8) of Regulation (EC) No 726/2004, the following fees shall apply:
- 6.7.1. a fee of EUR 210 200 where one active substance or combination of active substances and one marketing authorisation holder are included in the assessment. The remuneration shall be EUR 27 300 for the rapporteur and EUR 27 300 for the co-rapporteur;
- 6.7.2. a fee of EUR 296 400 where two or more active substances or combinations of active substances and one marketing authorisation holder are included in the assessment. The remuneration shall be EUR 31 600 for the rapporteur and EUR 31 600 for the co-rapporteur;
- 6.7.3. a fee of EUR 360 600 where one or two active substances or combinations of active substances and two or more marketing authorisation holders are included in the assessment. The remuneration shall be EUR 38 400 for the rapporteur and EUR 38 400 for the co-rapporteur;
- 6.7.4. a fee of EUR 489 200 where more than two active substances or combinations of active substances and two or more marketing authorisation holders are included in the assessment. The remuneration shall be EUR 52 100 for the rapporteur and EUR 52 100 for the co-rapporteur.

- 6.8. Where two or more marketing authorisation holders are involved in the procedures referred to in points 6.4, 6.5, 6.6 and 6.7, the amount payable by each marketing authorisation holder shall be calculated by the Agency in two steps, as follows:
- (a) by dividing the total amount of the fee among the marketing authorisation holders proportionally to the number of chargeable units-human corresponding to products included in the procedure which are held by each of those marketing authorisation holders;
 - (b) by subsequently applying, where relevant, the fee reduction laid down in Annex V.

7. Evaluation of traditional herbal medicinal products in accordance with Article 57(1)(n) of Regulation (EC) No 726/2004

A fee of EUR 34 000 shall apply to a request for scientific advice from the Committee on Herbal Medicinal Products related to traditional herbal medicinal products. The remuneration shall be EUR 4 900 for the rapporteur.

8. Certification of compliance with Union legislation for a plasma master file (PMF) in accordance with Part III of Annex I of Directive 2001/83/EC

8.1. A fee of EUR 66 000 shall apply to an application for review of a PMF and its initial certification pursuant to Part III, point 1.1 of Annex I to Directive 2001/83/EC. The remuneration shall be EUR 10 300 for the rapporteur and EUR 10 300 for the co-rapporteur.

8.2. A charge of EUR 6 600 shall apply to the issuing of an initial PMF certification where it is submitted simultaneously with an application for a marketing authorisation for a medicinal product under the centralised procedure. The PMF documentation shall be evaluated within the centralised marketing authorisation application.

8.3. A fee of EUR 12 200 shall apply to an application for review and certification of a major variation of type II to the PMF pursuant to Regulation (EC) No 1234/2008. The remuneration shall be EUR 1 900 for the rapporteur and EUR 1 900 for the co-rapporteur.

For two or more major variations of type II grouped in a single application pursuant to Regulation (EC) No 1234/2008, the fee and remuneration laid down in point 8.4 of this Annex shall apply.

8.4. A fee of EUR 19 500 shall apply for an application for review and annual re-certification of a PMF which may include any variation pursuant to Regulation (EC) No 1234/2008 submitted simultaneously with the application for a PMF annual re-certification. The remuneration shall be EUR 2 300 for the rapporteur and EUR 2 300 for the co-rapporteur.

9. Certification of compliance with Union legislation for a vaccine antigen master file (VAMF) in accordance with Part III of Annex I of Directive 2001/83/EC

- 9.1. A fee of EUR 66 000 shall apply for an application for review of a VAMF and its initial certification not submitted simultaneously with a new application for marketing authorisation under the centralised procedure pursuant to Part III, point 1.2 of Annex I to Directive 2001/83/EC. The remuneration shall be EUR 10 300 for the rapporteur and EUR 10 300 for the co-rapporteur.
- 9.2. In the case of a group of antigens aimed at preventing a single infectious disease, a fee shall be charged for the VAMF application for one antigen and remuneration shall be paid pursuant to point 9.1. The second and subsequent VAMF applications submitted simultaneously for antigens as part of the same group shall be charged a fee of EUR 9 100 per VAMF. The maximum total amount charged by the Agency for VAMF applications submitted simultaneously for antigens as part of the same group shall not exceed EUR 78 000. In that case, the remuneration per each second and subsequent VAMF shall be EUR 2 300 for the rapporteur and EUR 2 300 for the co-rapporteur.
- 9.3. A charge of EUR 6 600 shall apply to an application for issuing each VAMF certification where it is submitted simultaneously with a new application for marketing authorisation under the centralised procedure.
- 9.4. A fee of EUR 12 200 shall apply to an application for review and certification of a major variation of type II to the VAMF pursuant to Regulation (EC) No 1234/2008. The remuneration shall be EUR 1 800 for the rapporteur and EUR 1 800 for the co-rapporteur.

For each major variation of type II that is grouped in a single application made pursuant to Regulation (EC) No 1234/2008 a fee shall be charged as set out in the first subparagraph of this point.

10. Certification of quality and non-clinical data relating to advanced therapy medicinal products (ATMPs) developed by small and medium-sized enterprises (SMEs) in accordance with Regulation (EC) No 1394/2007 of the European Parliament and of the Council

- 10.1 A fee of EUR 165 600 shall apply to an application for evaluating and certifying the quality and non-clinical data pursuant to Article 18 of Regulation (EC) No 1394/2007 of the European Parliament and of the Council⁵². Such fee shall be waived in full. The remuneration shall be EUR 56 900 for the rapporteur.
- 10.2. A fee of EUR 110 100 shall apply to an application for evaluating and certifying only the quality data pursuant to Article 18 of Regulation (EC) No 1394/2007. Such fee shall be waived in full. The remuneration shall be EUR 37 800 for the rapporteur.

11. Paediatric applications in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council⁵³

- 11.1. A fee of EUR 36 400 shall apply to an application for agreement of a paediatric investigation plan requested pursuant to Article 15 of Regulation (EC) No 1901/2006. Such fee shall be waived in full. The remuneration shall be EUR 8 000 for the rapporteur.
- 11.2. A fee of EUR 20 400 shall apply to an application for a modification of an agreed paediatric investigation plan pursuant to Article 22 of Regulation (EC) No 1901/2006. Such fee shall be waived in full. The remuneration shall be EUR 7 700 for the rapporteur.
- 11.3. A fee of EUR 13 700 shall apply to an application for a product-specific waiver pursuant to Article 13 of Regulation (EC) No 1901/2006. Such fee shall be waived in full. The remuneration shall be EUR 2 200 for the rapporteur.
- 11.4. A fee of EUR 9 100 shall apply to a request for compliance check with the paediatric investigation plan pursuant to Article 23 of Regulation (EC) No 1901/2006. Such fee shall be waived in full. The remuneration shall be EUR 1 200 for the rapporteur.

⁵² Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (OJ L 324, 10.12.2007, p. 121).

⁵³ Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (OJ L 378, 27.12.2006, p. 1).

12. Orphan designation in accordance with Regulation (EC) No 141/2000 of the European Parliament and of the Council⁵⁴

A fee of EUR 19 200 shall apply to an application for or reassessment of the designation of an orphan medicinal product pursuant to Regulation (EC) No 141/2000. Such fee shall be waived in full. The remuneration shall be EUR 1 800 for the rapporteur.

13. Scientific opinion on the evaluation of medicinal product intended exclusively for markets outside the Union

A fee and corresponding remuneration as specified in points 1 to 5 of this Annex and sections 1, 3, 4 and 5 of Annex IV and points 6.1, 6.2 and 6.4 thereof shall apply for an application for a scientific opinion following the evaluation of a medicinal product intended exclusively for markets outside the Union pursuant to Article 58 of Regulation (EC) No 726/2004.

14. Periodic safety update reports

14.1 A fee of EUR 32 600 shall apply per procedure for the assessment of periodic safety update reports referred to in Articles 107e and 107g of Directive 2001/83/EC and in Article 28 of Regulation (EC) No 726/2004. The remuneration shall be EUR 16 600 for the rapporteur.

14.2. Where two or more marketing authorisation holders are subject to the obligation to submit periodic safety update reports in the context of the procedures referred to in point 14.1, the amount payable by each marketing authorisation holder shall be calculated by the Agency in two steps, as follows:

- (a) by dividing the total amount of the fee among the marketing authorisation holders proportionally to the number of chargeable units-human corresponding to products included in the procedure which are held by each of those marketing authorisation holders;
- (b) by subsequently applying, where relevant, the fee reduction laid down in point 1 of Annex V.

15. Post-authorisation safety studies

15.1. A fee of EUR 102 400 shall apply to an assessment carried out under Articles 107n to 107q of Directive 2001/83/EC and Article 28b of Regulation (EC) No 726/2004 of post-authorisation safety studies as referred to in Article 21a, point (b), or Article 22a(1), point (a), of Directive 2001/83/EC, or in Article 9(4), point (cb), or Article 10a(1), point (a), of Regulation (EC) No 726/2004, that are conducted in more than one Member State.

⁵⁴ Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (OJ L 18, 22.1.2000, p. 1).

- 15.2 The fee shall be charged in two instalments, as follows:
- 15.2.1. EUR 51 200 shall be due on the date of the start of the procedure for the assessment of the draft protocol referred to in Article 107n of Directive 2001/83/EC; the remuneration shall be EUR 21 400 for the rapporteur.
- 15.2.2 EUR 51 200 shall be due at the date of the start of the procedure for the assessment of the final study report, as referred to in Article 107p of Directive 2001/83/EC, by the Pharmacovigilance Risk Assessment Committee; the remuneration shall be EUR 21 400 for the rapporteur.
- 15.3. Where the obligation to conduct a post-authorisation safety study is imposed by the Commission on more than one marketing authorisation holder, the same concerns apply to more than one medicinal product and the marketing authorisation holders concerned conduct a joint post-authorisation safety study, the Agency shall calculate the amount payable by each marketing authorisation holder in two steps, as follows:
- (a) by evenly dividing the total amount of the fee among those marketing authorisation holders;
- (b) by subsequently applying the fee reduction as set out in point 1 of Annex V, where relevant.
- 15.4 Marketing authorisation holders who are charged the fee under this point shall be exempted from the payment of any other fee charged by the Agency or competent authorities of the Member State for the submission of the studies referred to in paragraph 15.1.

ANNEX II

Fees, charges and remuneration for assessment procedures and services relating to veterinary medicinal products

1. Scientific advice in accordance with Article 57(1)(n) of Regulation (EC) No 726/2004

1.1. A fee of EUR 34 900 shall apply to any of the following requests:

- (a) a request on quality, safety and clinical development;
- (b) a request on quality and clinical development;
- (c) a request on safety and clinical development;

The remuneration shall be EUR 16 700 for the scientific advice co-ordinator.

1.2. A fee of EUR 25 600 shall apply to any of the following requests:

- (a) a request on clinical development;
- (b) a request on quality and safety development;
- (c) a request on quality development and bioequivalence studies for generic veterinary medicinal products as defined in Article 4(9) of Regulation (EU) 2019/6.

The remuneration shall be EUR 10 600 for the scientific advice co-ordinator.

1.3. A fee of EUR 22 500 shall apply to a request related to any of the following:

- (a) a request on quality development;
- (b) a request on safety development;
- (c) a request on bioequivalence studies for generic veterinary medicinal products as defined in Article 4(9) of Regulation (EU) 2019/6;
- (d) a request for preliminary risk profile;
- (e) a request related to setting a new maximum residue limit.

The remuneration shall be EUR 6 400 for the scientific advice co-ordinator.

2. Request for classification of a veterinary medicinal product as intended for a limited market as defined in Article 4, point (29), of Regulation (EU) 2019/6 and for consideration for eligibility for authorisation in accordance with Article 23 of that Regulation

A charge of EUR 5 500 shall apply to a request for classification of a veterinary medicinal product as intended for a limited market within the meaning of Article 4(29) of Regulation (EU) 2019/6 and for consideration for eligibility for authorisation pursuant to Article 23 of Regulation (EU) 2019/6.

- 3. Establishment, modification or extension of a maximum residue limit (MRL) in accordance with the procedure laid down in Regulation (EC) No 470/2009 of the European Parliament and of the Council⁵⁵**
- 3.1. A fee of EUR 89 300 shall apply to an application to set an initial MRL for a given substance. The remuneration shall be EUR 22 600 for the rapporteur and EUR 10 900 for the co-rapporteur.
- 3.2. A fee of EUR 55 900 shall apply to each application to modify or to extend an existing MRL. The remuneration shall be EUR 11 200 for the rapporteur and EUR 10 200 for the co-rapporteur.
- 3.3. A fee of EUR 25 600 shall apply to the assessment to determine whether a chemical-unlike biological substance requires a full MRL evaluation or not pursuant to Annex I, Section I.7, to Commission Regulation (EU) 2018/78256. The remuneration shall be EUR 10 600 for the rapporteur.
- 4. Authorisation to market veterinary medicinal products falling within the scope of the centralised marketing authorisation procedure pursuant to Article 42 of Regulation (EU) 2019/6**
- 4.1. A fee of EUR 311 500 shall apply to an application for a marketing authorisation for a veterinary medicinal product pursuant to Articles 8, 23 or Article 25 of Regulation (EU) 2019/6 where the applicant claims a new active substance. That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application, irrespective of the number of target species. The remuneration shall be EUR 112 800 for the rapporteur and EUR 40 200 for the co-rapporteur.
- 4.2. A fee of EUR 282 200 shall apply to an application for a marketing authorisation for a veterinary medicinal product pursuant to Articles 8, 20, 22, 23 or Article 25 of Regulation (EU) 2019/6 where the applicant claims a known active substance. That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application, irrespective of the number of target species. The remuneration shall be EUR 86 500 for the rapporteur and EUR 37 200 for the co-rapporteur.

⁵⁵ Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 152, 16.6.2009, p. 11).

⁵⁶ Commission Regulation (EU) 2018/782 of 29 May 2018 establishing the methodological principles for the risk assessment and risk management recommendations referred to in Regulation (EC) No 470/2009 (OJ L 132, 30.5.2018, p. 5).

4.3. A fee of EUR 144 200 shall apply for any of the following applications:

- (a) an application for a marketing authorisation for a generic veterinary medicinal product pursuant to Article 18 of Regulation (EU) 2019/6;
- (b) an application for a marketing authorisation for a hybrid veterinary medicinal product pursuant to Article 19 of Regulation (EU) 2019/6;
- (c) an application based on informed consent for a marketing authorisation for a veterinary medicinal product pursuant to Article 21 of Regulation (EU) 2019/6.

That fee shall cover all strengths, all pharmaceutical forms and all presentations submitted in the same application, irrespective of the number of target species. The remuneration shall be EUR 32 500 for the rapporteur and EUR 18 900 for the co-rapporteur.

5. Re-examination of a marketing authorisation for limited markets

A fee of EUR 20 000 shall apply to an application for a re-examination of a marketing authorisation for a limited market pursuant to Article 24(3) of Regulation (EU) 2019/6. The remuneration shall be EUR 3 300 for the rapporteur and EUR 2 500 for the co-rapporteur.

6. Variations to the terms of a marketing authorisation, requiring assessment in accordance with Articles 64, 65 and 66 of Regulation (EU) 2019/6

- 6.1. A fee of EUR 92 600 shall apply to a variation requiring assessment introducing changes of active substance(s), strength, pharmaceutical form, route of administration or food-producing target species, which are to be assessed within 90 days in accordance with Article 66(3) of Regulation (EU) 2019/6. That fee shall be charged for each single pharmaceutical form or each single associated strength/potency. The remuneration shall be EUR 30 100 for the rapporteur and EUR 9 100 for the co-rapporteur.
- 6.2. A fee of EUR 50 100 shall apply to variations requiring assessment that introduce changes to safety, efficacy or pharmacovigilance, which are to be assessed within 60 or 90 days, as the case may be, in accordance with Article 66(3) of Regulation (EU) 2019/6. The remuneration shall be EUR 10 300 for the rapporteur and EUR 8 000 for the co-rapporteur.
- 6.3. A fee of EUR 25 200 shall apply to variations requiring assessment introducing quality changes only, which are to be assessed within 60 days in accordance with Article 66(3) of Regulation (EU) 2019/6. The remuneration shall be EUR 3 800 for the rapporteur and EUR 3 800 for the co-rapporteur.

- 6.4. Where several variations requiring assessment are grouped in a single application under Article 64 of Regulation (EU) 2019/6, the corresponding fee as set out in points 6.1, 6.2 and 6.3 of this Annex shall apply to each of the first two variations. Remuneration shall be paid in accordance with those points. For the third and subsequent variations, the fee shall be EUR 12 600 per variation and the remuneration shall be EUR 1 900 per variation for the rapporteur and EUR 1 900 for the co-rapporteur.
- 6.5. Where a work-sharing application pursuant to Article 65 of Regulation (EU) 2019/6 includes more than one centrally authorised product, the fees and remuneration specified in points 6.1, 6.2 and 6.3 of this Annex shall apply for each variation to the first centrally authorised product, whereas a charge of EUR 800 shall apply for each variation to the second and subsequent centrally authorised product included in the same application.

7. Referrals and arbitration procedures

- 7.1. A fee of EUR 161 000 shall apply to an assessment carried out in the context of a procedure initiated under Article 54(8) of Regulation (EU) 2019/6. Such fee shall be waived in full. The remuneration shall be EUR 22 200 for the rapporteur and EUR 10 100 for the co-rapporteur.
- 7.2. A fee of EUR 220 600 shall apply to the assessment carried out in the context of a procedure initiated under Article 70(11) of Regulation (EU) 2019/6. Such fee shall be waived in full. The remuneration shall be EUR 30 800 for the rapporteur and EUR 13 600 for the co-rapporteur.
- 7.3. A fee of EUR 155 200 shall apply to the assessment carried out pursuant to Article 141(1), points (c) and (e), of Regulation (EU) 2019/6. Such fee shall be waived in full. The remuneration shall be EUR 18 400 for the rapporteur and EUR 8 100 for the co-rapporteur.
- 7.4. A fee of EUR 220 600 shall apply to the assessment carried out in the context of a procedure initiated under Article 82 of Regulation (EU) 2019/6. The remuneration shall be EUR 30 800 for the rapporteur and EUR 13 600 for the co-rapporteur.
- 7.5. A fee of EUR 155 200 shall apply for the assessment carried out in the context of a procedure initiated under Article 129(3) or Article 130(4) of Regulation (EU) 2019/6. The remuneration shall be EUR 18 400 for the rapporteur and EUR 8 100 for the co-rapporteur.

- 7.6. Where two or more marketing authorisation holders are involved in the procedures referred to in points 7.4 or 7.5, the amount payable by each marketing authorisation holder shall be calculated by the Agency in two steps, as follows:
- (a) by dividing the total amount of the fee among the marketing authorisation holders proportionally to the number of chargeable units – veterinary corresponding to products included in the procedure which are held by each of those marketing authorisation holders;
 - (b) by subsequently applying the fee reduction laid down in point 1 of Annex V, where relevant.

8. Certification of compliance with Union legislation for vaccine antigen master files (VAMF)

- 8.1. A fee of EUR 25 200 shall apply to an application for review of a VAMF and its certification pursuant to point V.2 of Annex II to Regulation (EU) 2019/6 when it is submitted simultaneously with an initial application for marketing authorisation for a veterinary medicinal product under the centralised procedure containing the named antigen. The remuneration shall be EUR 3 800 for the rapporteur and EUR 3 800 for the co-rapporteur.
- 8.2. For multiple VAMF applications submitted simultaneously in the context of the same initial marketing authorisation application, a fee of EUR 25 200 shall apply per VAMF. The maximum total amount charged by the Agency shall not exceed EUR 74 800. The remuneration shall be EUR 3 800 for the rapporteur and EUR 3 800 for the co-rapporteur. For multiple VAMF applications submitted simultaneously in the context of the same initial marketing authorisation application, the remuneration shall not exceed EUR 11 400 for the rapporteur and EUR 11 400 for the co-rapporteur.
- 8.3. A fee of EUR 34 900 shall apply to an application for the review of a VAMF and its certification when submitted as a separate application for an antigen in vaccine(s) already authorised under the centralised, decentralised or mutual recognition procedure. The remuneration shall be EUR 5 300 for the rapporteur and EUR 5 300 for the co-rapporteur.
- 8.4. Section 6 of this Annex shall apply by analogy to variations to a certified VAMF.

9. Certification of compliance with Union legislation for vaccine platform technology master files (vPTMF)

- 9.1. A fee of EUR 25 200 shall apply to an application for review of a vPTMF and its certification pursuant to point V.4 of Annex II to Regulation (EU) 2019/6 when submitted simultaneously with an initial application for marketing authorisation for a veterinary medicinal product under the centralised procedure containing the named platform. The remuneration shall be EUR 3 800 for the rapporteur and EUR 3 800 for the co-rapporteur.
- 9.2. A fee of EUR 34 900 shall apply to an application for review of a vPTMF and its certification when submitted as a separate application for a platform in vaccines already authorised under the centralised, decentralised or mutual recognition procedure. The remuneration shall be EUR 5 300 for the rapporteur and EUR 5 300 for the co-rapporteur.
- 9.3. Section 6 of this Annex shall apply by analogy to variations to a certified vPTMF.

10. Assessment of post-marketing surveillance studies

- 10.1 A fee of EUR 39 800 shall apply to the assessment of post-marketing surveillance studies pursuant to Article 76(3) of Regulation (EU) 2019/6 that are conducted in more than one Member States.
- 10.2. The fee shall be charged as follows:
- (a) EUR 19 900 shall be due at the date of the start of the procedure for the approval of the draft study protocol as referred to in Article 15(3) of Commission Implementing Regulation (EU) 2021/1281⁵⁷. The remuneration shall be EUR 8 100 for the rapporteur;
 - (b) EUR 19 900 shall be due at the date of the start of the procedure for the assessment of the final study report as referred to in Article 15(5) of Implementing Regulation (EU) 2021/1281. The remuneration shall be EUR 8 100 for the rapporteur.

⁵⁷ Commission Implementing Regulation (EU) 2021/1281 of 2 August 2021 laying down rules for the application of Regulation (EU) 2019/6 of the European Parliament and of the Council as regards good pharmacovigilance practice and on the format, content and summary of the pharmacovigilance system master file for veterinary medicinal products (OJ L 279, 3.8.2021, p. 15).

10.3. Where the obligation to conduct a post-marketing surveillance study is imposed on more than one marketing authorisation holder and the marketing authorisation holders concerned conduct a joint post-marketing surveillance study, the Agency shall calculate the fee to be charged in two steps, as follows:

- (a) by evenly dividing the total amount of the fee among those marketing authorisation holders;
- (b) by subsequently applying the fee reduction as set out in Annex V, point 1, where relevant.

11. Scientific opinions in the context of cooperation with international organisations for animal health for the evaluation of veterinary medicinal products intended exclusively for markets outside the Union

A fee and corresponding remuneration as specified in points 1, 3, 4 and 6 of this Annex and in points 1, 3, 4 and 5 of Annex IV and points 6.1, 6.2 and 6.4 of that Annex to this Regulation shall apply for an application for a scientific opinion for the evaluation of veterinary medicinal products intended exclusively for markets outside the Union pursuant to Article 138 of Regulation (EU) 2019/6.

ANNEX III

Annual fees and remuneration

1. Annual fee for medicinal products for human use authorised in accordance with Regulation (EC) No 726/2004

- 1.1. An annual fee of EUR 57 700 shall apply to each marketing authorisation of a medicinal product for human use authorised on the basis of an application submitted under Article 10(1) and (3) and Article 10c of Directive 2001/83/EC. The remuneration shall be EUR 7 700 for the rapporteur, EUR 6 700 for the co-rapporteur and 1 400 for the PRAC-rapporteur.
- 1.2. An annual fee of EUR 113 000 shall apply to each marketing authorisation of a medicinal product for human use authorised on the basis of an application submitted under Article 10(4) of Directive 2001/83/EC. The remuneration shall be EUR 15 500 for the rapporteur, EUR 13 700 for the co-rapporteur and 2 900 for the PRAC-rapporteur.
- 1.3. An annual fee of EUR 222 300 shall apply to each marketing authorisation of a medicinal product for human use not covered by point 1.1 or 1.2. The remuneration shall be EUR 30 800 for the rapporteur, EUR 27 200 for the co-rapporteur and 5 800 for the PRAC-rapporteur.

1.3a.(new) The annual fees as specified in points 1.1, 1.2 and 1.3 shall relate to the preceding year.

2. Annual fee for veterinary medicinal products authorised through the centralised procedure in accordance with Regulation (EU) 2019/6

- 2.1. An annual fee of EUR 25 000 shall apply for each marketing authorisation of a veterinary medicinal product authorised pursuant to Article 18, 19 or 21 of Regulation (EU) 2019/6. The remuneration shall be EUR 6 000 for the rapporteur and EUR 5 500 for the co-rapporteur.
- 2.2. An annual fee of EUR 101 800 shall apply to each marketing authorisation not covered by point 2.1. The remuneration shall be EUR 24 500 for the rapporteur and EUR 22 600 for the co-rapporteur.

2.2a.(new) The annual fees as specified in points 2.1 and 2.2 shall relate to the preceding year.

- 3. Annual pharmacovigilance fee for medicinal products for human use authorised in accordance with Directive 2001/83/EC and for veterinary medicinal products authorised by competent authorities of the Member States in accordance with Regulation (EU) 2019/6**
- 3.1. For medicinal products for human use authorised in accordance with Directive 2001/83/EC, a fee of EUR 220 per chargeable unit-human, shall apply once per year for the Agency's pharmacovigilance activities including analysis of Union-wide health data to support better decision-making with real world evidence. The Agency shall retain the fee revenue from the annual pharmacovigilance fee.
- 3.2. For veterinary medicinal products authorised by competent authorities of the Member States in accordance with Chapter III, Sections 2 to 5 of Regulation (EU) 2019/6, a fee of EUR 90 per chargeable unit-veterinary shall apply once per year for the Agency's pharmacovigilance activities. The Agency shall retain the fee revenue from the annual pharmacovigilance fee.
- 3.3. The total payable amount of the annual fees referred to in points 3.1 and 3.2 for each marketing authorisation holder shall be calculated by the Agency on the basis of the number of chargeable units-human and chargeable units-veterinary, respectively, which correspond to the information recorded on 1 July of each year.
- 3.4. The annual fees referred to in points 3.1 and 3.2 shall be due on 1 July of every year and shall cover the period from 1 January to 31 December of that calendar year.

ANNEX IV

Other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices

1. **Inspections pursuant to Article 8(2), 19 and Article 57(1), point (i) of Regulation (EC) No 726/2004 and article 126(2) of Regulation No 2019/6**
 - 1.1. Inspections in relation to medicinal products for human use and veterinary medicinal products
 - 1.1.1. For any distinct Good Manufacturing Practice inspection within the Union a fee of EUR 29 000 shall apply. The remuneration shall be EUR 10 300 for the leading authority and EUR 6 200 for the supporting authority.
 - 1.1.2. For any distinct Good Manufacturing Practice inspection outside the Union a fee of EUR 56 000 shall apply. The remuneration shall be EUR 24 800 for the leading authority and EUR 16 700 for the supporting authority.
 - 1.1.3. For any distinct Good Clinical Practice inspection within the Union a fee of EUR 43 700 shall apply. The remuneration shall be EUR 17 600 for the leading authority and EUR 10 900 for the supporting authority.
 - 1.1.4. For any distinct Good Clinical Practice inspection outside the Union a fee of EUR 56 600 shall apply. The remuneration shall be EUR 25 800 for the leading authority and EUR 14 700 for the supporting authority.
 - 1.1.5. For any distinct Plasma Master File inspection within or outside the Union a fee of EUR 47 300 shall apply. The remuneration shall be EUR 16 700 for the leading authority and EUR 14 100 for the supporting authority.
 - 1.1.6. For any consecutive Plasma Master File inspection within or outside the Union a fee of EUR 42 400 shall apply. The remuneration shall be EUR 16 100 for the leading authority and EUR 9 800 for the supporting authority.

1.1.7. For any distinct Good Laboratory Practice inspection within or outside the Union a fee of EUR 41 000 shall apply. The remuneration shall be EUR 15 800 for the leading authority and EUR 10 400 for the supporting authority.

1.1.8. For any distinct pharmacovigilance inspection within or outside the Union a fee of EUR 61 500 shall apply. The remuneration shall be EUR 19 400 for the leading authority and EUR 12 100 for the supporting authority.

- 1.2. If a scheduled inspection is cancelled 30 calendar days or less before the first day of the inspection for reasons attributable to the applicant, the applicable fee referred to in point 1.1 shall apply.
- 1.3. If a scheduled inspection is cancelled more than 30 calendar days before the first day of the inspection for reasons attributable to the applicant, a charge of EUR 1 000 shall apply.
- 1.4. The supervisory authorities shall charge the applicant the travel expenses separately from the fee specified in this Annex, based on actual cost. In case of a cancelled inspection as per points 1.2 or 1.3, the applicant shall be charged for any travel expenses already incurred by the inspecting authority on the date of cancellation for which that authority is not able to obtain reimbursement.

2. Transfer of a marketing authorisation

A charge of EUR 4 200 shall apply to an application for the transfer of a marketing authorisation pursuant to Article 3 of Commission Regulation (EC) No 2141/96⁵⁸. This covers all authorised presentations of a given medicinal product.

The charge shall be levied to the marketing authorisation holder that requested the transfer, according to the application submitted to the Agency.

⁵⁸ Commission Regulation (EC) No 2141/96 of 7 November 1996 concerning the examination of an application for the transfer of a marketing authorization for a medicinal product falling within the scope of Council Regulation (EC) No 2309/93 (OJ L 286, 8.11.1996, p. 6).

3. Pre-submission requests by a prospective applicant prior to a potential submission of an application for a marketing authorisation falling within the scope of the centralised procedure

- 3.1. A fee of EUR 8 200 shall apply to each eligibility request submitted with a notification of intention to submit an application for a marketing authorisation falling within the scope of Regulation (EC) No 726/2004 or the scope of the centralised marketing authorisation procedure pursuant to Article 42 of Regulation (EU) 2019/6. The fee shall cover any costs related to pre-submission activities up until the potential submission of the marketing authorisation application. The fee shall apply irrespective of whether or not a marketing authorisation application for the concerned product is subsequently submitted. If an eligibility request has not been submitted, the fee shall apply in addition to the applicable authorisation fee.

The remuneration of the national competent authority, where applicable, shall be EUR 1 600 for the rapporteur and EUR 1 600 for the co-rapporteur.

- 3.2. Where the applicant changes the intended submission date by more than 60 days, an additional fee of EUR 4 000 shall apply. The additional remuneration of the national competent authority, where applicable, shall be EUR 700 for the rapporteur and EUR 700 for the co-rapporteur.

4. Re-examination of an opinion of the Committees referred to in Article 56(1) of Regulation (EC) No 726/2004 and in Article 139(1) of Regulation (EU) 2019/6

The fee for the re-examination of an opinion of any of the committees referred to in Article 56(1) of Regulation (EC) No 726/2004 and in Article 139(1) of Regulation (EU) 2019/6 shall be 30% of the fee applicable to the initial opinion in accordance with points 3, 4, 5 and 6 of Annex I and points 3, 4, 6 and 7 of Annex II to this Regulation. The remuneration to the rapporteur and the co-rapporteur shall be calculated based on the same proportion of the respective remuneration.

5. Scientific services referred to in Article 4(1)

The range for fees for scientific services referred to in Article 4(1) shall be EUR 4 800 to EUR 805 100. The range for the remuneration shall be EUR 1 200 to EUR 261 000 for the rapporteur and the co-rapporteur. The applicable amounts of the fee and the remuneration within the above ranges shall be determined in accordance with Article 8.

6. Administrative services

6.1. Administrative charge

A charge of EUR 4 200 shall apply for applications subject to a fee set out in Annex I or II in any of the following situations:

- (a) the application is withdrawn after 24 hours of its submission and prior to completion of the administrative validation;
- (b) the application has been rejected following the conclusion of the administrative validation.

In the cases referred to in the previous subparagraph, the corresponding fee shall not be levied.

In addition to the applicable fee or charge set out in Annexes I, II or Annex III, a charge of EUR 4 200 shall also apply to applications where a marketing authorisation holder or an applicant claiming, or having claimed, to be entitled to a fee reduction, fails to demonstrate that it is entitled to such a reduction.

6.2. Certificates of medicinal products as referred to in Article 127 of Directive 2001/83/EC and in Article 98 of Regulation (EU) 2019/6

6.2.1 A charge of EUR 160 shall apply to each request for a certificate issued by the Agency for a medicinal product, using the standard procedure for issuing the certificate.

6.2.2. A charge of EUR 480 shall apply to each request for a certificate issued by the Agency for a medicinal product, using the urgent procedure for issuing the certificate.

6.3. Notification of parallel distribution in accordance with Article 57(1), point (o), of Regulation (EC) No 726/2004

6.3.1. A charge of EUR 1 400 shall apply to each initial notification for each presentation of a medicinal product, for one Member State of destination having one or more official languages or for several Member States of destination having the same official language. That charge shall cover any subsequent safety update notification relating to the initial notification.

6.3.2. A charge of EUR 400 shall apply to each notification of a bulk change. That charge shall cover all initial notifications approved by the date of submission of the notification of bulk changes.

6.3.3. A charge of EUR 400 shall apply to each annual update notification. That charge shall cover all the presentations belonging to the same medicinal product for one Member State of destination having one or more official languages, or for several Member States of destination having the same official language. No charge shall apply if there have been no regulatory updates in the past twelve months or if the product was dormant.

6.4. **Administrative services referred to in Article 4(2)**

The range of charges for other administrative services referred to in Article 4(2) shall be from EUR 110 to EUR 11 300. The applicable amounts of the charge within the above range shall be determined in accordance with Article 8.

7. **Consultation on medical devices**

7.1. *Ancillary substances incorporated in medical devices*

7.1.1. A fee of EUR 109 700 shall apply to a consultation on one or more ancillary medicinal substances pursuant to section 5.2 of Annex IX to Regulation (EU) 2017/745, where the medicinal substance(s) from the specified manufacturer has not been evaluated by the Agency or a competent authority designated by the Member States in accordance with Directive 2001/83/EC (hereafter ‘medicinal products authority’) in connection with a previous marketing authorisation or through a previous consultation by a notified body. One application may include a range of strength or concentrations of the ancillary substance(s) or a range of similar devices from the same medical device manufacturer incorporating the same substance(s) or both. The remuneration shall be EUR 28 200 for the rapporteur and EUR 28 200 for the co-rapporteur.

7.1.2. A fee of EUR 54 700 shall apply to a consultation on one or more ancillary medicinal substance(s) pursuant to section 5.2 of Annex IX to Regulation (EU) 2017/745, where the medicinal substance(s) from the specified manufacturer has been evaluated by a medicinal products authority in connection with a previous marketing authorisation or through a previous consultation by a notified body. One application may include a range of strengths or concentrations of the ancillary substance(s) or a range of similar devices from the same medical device manufacturer incorporating the same substance(s) or both. The remuneration shall be EUR 13 800 for the rapporteur and EUR 13 800 for the co-rapporteur.

7.1.3. For the purpose of 7.1.1. and 7.1.2., a fee of EUR 4 700 shall apply to a consultation, pursuant to section 5.2, point (f), of Annex IX to Regulation (EU) 2017/745, regarding a change with respect to an ancillary medicinal substance incorporated in a device. The remuneration shall be EUR 1 700 for the rapporteur.

- 7.2. Medical devices composed of a substance or a combination of substances that are systemically absorbed to achieve their intended purpose.

A fee of EUR 82 400 shall apply to a consultation on a medical device or a range of similar devices composed of a substance or a combination of substances that are absorbed by or locally dispersed in the human body, pursuant to section 5.4 of Annex IX, to Regulation (EU) 2017/745. The remuneration shall be EUR 21 000 for the rapporteur and EUR 21 000 for the co-rapporteur.

7.3. *Companion diagnostic*

7.3.1. A fee of EUR 54 000 shall apply to a consultation on the suitability of a companion diagnostic in relation to a concerned medicinal product, pursuant to Article 48(3) or (4), of Regulation (EU) 2017/746, and section 5.2 of Annex IX, or section 3, point (k), of Annex X to that Regulation. The remuneration shall be EUR 14 200 for the rapporteur.

A fee of EUR 4 700 shall apply to a consultation on a change affecting the suitability of the companion diagnostic in relation to the medicinal product concerned, pursuant to section 5.2, point (f), of Annex IX to Regulation (EU) 2017/746. The remuneration shall be EUR 1 700 for the rapporteur.

- 7.4. The fees set out in points 7.1, 7.2 and 7.3 shall be charged to the medical device manufacturer that, according to the application form submitted to the Agency, requested the assessment of conformity of the medical device for which the notified body is consulting the Agency.

ANNEX V

Fee reductions

1. Fee reductions granted to micro, small- and medium-sized enterprises

1.1. The following total or partial reductions to the fees laid down in this Regulation shall be granted to micro, small and medium-sized enterprises:

1.1.1 for a small or medium-sized enterprise, a fee reduction of 40 % of the applicable amount shall apply to the following fees:

(a) extension of a marketing authorisation for medicinal products for human use pursuant to section 4 of Annex I;

(b) major type-II variations for medicinal products for human use pursuant to section 5 of Annex I, excluding point 5.4 of that section;

(c) referral procedures for medicinal products for human use pursuant to points 6.4 to 6.7 of Annex I;

(d) request for scientific advice by the Committee on Herbal Medicinal Products related to traditional herbal medicinal products pursuant to section 7 of Annex I;

(e) certification of compliance with Union legislation for plasma master files pursuant to section 8 of Annex I;

(f) certification of compliance with Union legislation regarding vaccine antigen master files (VAMF) pursuant to section 9 of Annex I;

(g) assessment of periodic safety update reports for medicinal products for human use pursuant to section 14 of Annex I;

(h) assessment of post-authorisation safety studies for medicinal products for human use pursuant to section 15 of Annex I;

(i) variations requiring assessment pursuant to section 6 of Annex II, excluding point 6.5 of that section;

(j) referral procedures for veterinary medicinal products pursuant to points 7.4 to 7.5 of Annex II;

(k) certification of compliance with Union legislation regarding VAMF pursuant to section 8 of Annex II;

(l) certification of compliance with Union legislation regarding vaccine platform technology master files (vPTMF) pursuant to section 9 of Annex II;

(m) assessment of post-marketing surveillance studies for veterinary medicinal products pursuant to section 10 of Annex II;

(n) annual fee, for medicinal products for human use or for veterinary medicinal products, or both, pursuant to section 1 or 2, respectively, of Annex III;

(o) pharmacovigilance annual fee, for medicinal products for human use or veterinary medicinal products pursuant to Annex III;

(p) transfer of a marketing authorisation to another micro-, small- or medium-sized enterprise, both for medicinal products for human use and veterinary medicinal products pursuant to section 2 of Annex IV;

1.1.1. for a small or medium-sized enterprise, a fee reduction of 90 % of the applicable amount shall apply to a consultation on medical devices pursuant to section 7 of Annex IV, where the medical device manufacturer has been assigned the small and medium-sized enterprise status by the Agency;

1.1.2. for a micro enterprise, a reduction of 100 % shall apply to the fees set out in points 1.1.1. and 1.1.2.

1.2. The fee reductions set out in point 1.1.1 shall apply in addition to fee reductions and incentives provided for in Regulation (EC) No 2049/2005 or in the Union pharmaceutical legislation.

1.3. The reductions set out in point 1.1 shall not be granted to SMEs acting as applicant or marketing authorisation holder for the relevant medicinal product by virtue of a contractual arrangement with a non-SME legal entity. Such contractual arrangements shall be declared to the Agency ahead of any service listed under point 1.1.1.

2. Applications relating to core dossier medicinal products to be used in a human pandemic situation

2.1. The payment of the fee for an application for a marketing authorisation of a medicinal product to be used in a human pandemic situation shall be deferred until the pandemic situation is duly recognised, either by the World Health Organisation or by the Commission in accordance with Article 23(1) of Regulation (EU) 2022/2371 on serious cross-border threats to health and repealing Decision No 1082/2013/EU.

Such deferral shall not exceed 5 years.

2.2. In addition to the deferral provided for in point 2.1, for regulatory activities within the framework of the submission of a core dossier for a pandemic vaccine and the follow-up submission of a pandemic variation, a fee reduction of 100 % shall apply in the following cases:

- (a) pre-submission activities pursuant to section 3 of Annex IV;
- (b) scientific advice pursuant to section 1 of Annex I;
- (c) extension of marketing authorisation pursuant to section 4 of Annex I;
- (d) major type-II variation pursuant to section 5 of Annex I;
- (e) annual fee pursuant to section 1 of Annex III.

Those reductions shall apply until the human pandemic situation is duly recognised.

2.3. Where reductions apply pursuant to point 2.2, no remuneration shall be paid to the national competent authorities for the annual fees referred to in point 2.2(e).

3. Applications submitted under Article 30 of Regulation (EC) No 1901/2006

A 50 % fee reduction shall apply to paediatric use marketing authorisation applications submitted under Article 30 of Regulation (EC) No 1901/2006 for the following services:

- (a) initial marketing authorisation application pursuant to section 3 of Annex I, to this Regulation;
- (b) pre-authorisation inspection pursuant to section 1 of Annex IV, to this Regulation;
- (c) extension of a marketing authorisation pursuant to section 4 of Annex I, to this Regulation, in the first year from granting of the marketing authorisation;
- (d) major type-II variation pursuant to section 5 of Annex I, to this Regulation, in the first year from granting of a marketing authorisation;
- (e) annual fee pursuant to section 1 of Annex III, to this Regulation, in the first year from granting of a marketing authorisation;
- (f) post-authorisation inspection pursuant to section 1 of Annex IV, to this Regulation, in the first year from granting of a marketing authorisation.

4. Immunological veterinary medicinal products

A fee reduction of 50 % shall apply to immunological veterinary medicinal products for the following activities:

- (a) scientific advice pursuant to section 1 of Annex II;
- (b) request for classification of a veterinary medicinal product as intended for a limited market as defined in Article 4, point 29 of Regulation (EU) 2019/6 and for consideration for eligibility for authorisation according to Article 23 of that Regulation, pursuant to section 2 of Annex II, to this Regulation;
- (c) authorisation to market veterinary medicinal products falling within the scope of the centralised marketing authorisation procedure pursuant to Article 42 of Regulation (EU) 2019/6, pursuant to section 4 of Annex II, to this Regulation;
- (d) variations to the terms of a marketing authorisation requiring assessment in accordance with Article 66 of Regulation (EU) 2019/6, pursuant to Annex II, section 6, to this Regulation. In the specific case of point 6.5 of Annex II, the reduction shall apply to the variations subject to a fee and shall not apply to the variations subject to a charge;
- (e) certification of compliance with Union legislation for VAMF pursuant to section 8 of Annex II;
- (f) certification of compliance with Union legislation for vPTMF pursuant to section 9 of Annex II;
- (g) assessment of post-marketing surveillance studies pursuant to section 10 of Annex II;
- (h) annual fee pursuant to section 2 of Annex III;
- (i) pre-submission services pursuant to section 3 of Annex IV.

5. Veterinary medicinal products for limited markets

5.1. A fee reduction of 50 % shall apply to veterinary medicinal products classified as intended for a limited market within the meaning of Article 4(29) of Regulation (EU) 2019/6 and considered eligible for authorisation or authorised pursuant to Article 23 of that Regulation, for the following activities:

(a) scientific advice pursuant to section 1 of Annex II, to this Regulation;

(b) applications for establishment, modification or extension of a maximum residue limit pursuant to section 3 of Annex II, to this Regulation;

(c) authorisation to market veterinary medicinal products falling within the scope of the centralised marketing authorisation procedure pursuant to Article 42 of Regulation (EU) 2019/6 pursuant to Article 23 of that Regulation, pursuant to point 4.1 or 4.2 of Annex II, to this Regulation;

(d) variations to the terms of a marketing authorisation requiring assessment in accordance with Article 66 of Regulation (EU) 2019/6, pursuant to section 6 of Annex II. In the specific case of point 6.5 of Annex II, the reduction shall apply to the variations subject to a fee and shall not apply to the variations subject to a charge;

(e) certification of compliance with Union legislation for VAMF pursuant to section 8 of Annex II to this Regulation;

(f) certification of compliance with Union legislation for vPTMF pursuant to section 9 of Annex II to this Regulation;

(g) assessment of post-marketing surveillance studies pursuant to section 10 of Annex II, to this Regulation;

(h) annual fee pursuant to section 2 of Annex III, to this Regulation;

(i) pre-submission services pursuant section 3 to Annex IV, to this Regulation.

5.2. A reduction of 100 % shall apply to the fee for extension of maximum residues limits set out in section 3 of Annex II, when such extension does not require assessment of data.

6. Veterinary vaccines against certain major epizootic diseases

- 6.1. A fee reduction of 100 % shall apply to the annual fee for vaccines against infection with bluetongue virus (serotypes 1-24), highly pathogenic avian influenza, foot and mouth disease and classical swine fever, where the vaccine is authorised under normal circumstances and the product has not been marketed within the Union at any time during the totality of the period covered by the fee.
- 6.2. Where a reduction applies pursuant to point 6.1, no remuneration shall be paid to the national competent authorities for the annual fees referred to in point 6.1.

7. Annual fee for veterinary medicinal products

A fee reduction of 25 % shall apply to the annual fee for veterinary medicinal products set out in section 2 of Annex III, with the exclusion of those products already listed in sections 4 and 5 of this Annex.

8. Annual pharmacovigilance fee for generic, homeopathic and herbal medicinal products

A fee reduction of 20 % shall apply to the annual pharmacovigilance fee set out in section 3 of Annex III for the following medicinal products:

- (a) medicinal products for human use as referred to in Article 10(1) and Article 10a of Directive 2001/83/EC;
- (b) homeopathic medicinal products for human use;
- (c) herbal medicinal products for human use;
- (d) veterinary medicinal products as referred to in Articles 18 and 22 of Regulation (EU) 2019/6;
- (e) homeopathic veterinary medicinal products;
- (f) homeopathic veterinary medicinal products registered in accordance with Article 87 of Regulation (EU) 2019/6.

ANNEX VI

Performance information

The following information shall relate to each calendar year:

- (1) the overall cost and breakdown of Agency staff and non-staff costs relating to the fees and charges referred to in Article 3;
- (2) number of Agency staff involved and the overall costs for obtaining and maintaining a Union authorisation to market medicinal products for human use and veterinary medicinal products and for other services of the Agency;
- (3) number of procedures for obtaining and maintaining a Union authorisation to market medicinal products for human use and veterinary medicinal products and for other services of the Agency;
- (4) number and amount of fee reductions or waivers granted per type of fee reduction or waiver under Union Legislation and number of applicants or holders concerned;
- (5) attribution of rapporteurs, co-rapporteurs, or roles considered as equivalent for the purposes of this regulation as referred to in the Annexes to this regulation, per Member State, per type of procedure;
- (6) number of working hours spent by the rapporteur and the co-rapporteurs or roles considered as equivalent for the purposes of this regulation as referred to in the Annexes to this regulation, and experts contracted for the procedures of the expert panels on medical devices per type of procedures on the basis of the information provided to the Agency by the national competent authorities concerned. The types of procedures to be included shall be decided by the Management Board based on a proposal by the Agency.

ANNEX VII

Correlation table

Regulation 297/95	This Regulation
Article 8(1)	Annex I, point 1 and Annex II, point 1
Article 3(1)	Annex I, point 3
Article 7	Annex II, point 3
Article 5(1)	Annex II, point 4
Article 3(4)	Annex IV, point 1
Article 5(4)	Annex IV, point 1
Article 8(2)	Annex IV, point 5
Article 8(3)	Annex IV, points 6.1, 6.2 and 6.4